[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 715
1. Yukinawa N, Oba S, Kato K, Taniguchi K, Iwao-Koizumi K, Tamaki Y, Noguchi S, Ishii S: A multi-class predictor based on a probabilistic model: application to gene expression profiling-based diagnosis of thyroid tumors. BMC Genomics; 2006;7:190
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multi-class predictor based on a probabilistic model: application to gene expression profiling-based diagnosis of thyroid tumors.
  • BACKGROUND: Although microscopic diagnosis has been playing the decisive role in cancer diagnostics, there have been cases in which it does not satisfy the clinical need.
  • Differential diagnosis of malignant and benign thyroid tissues is one such case, and supplementary diagnosis such as that by gene expression profile is expected.
  • RESULTS: With four thyroid tissue types, i.e., papillary carcinoma, follicular carcinoma, follicular adenoma, and normal thyroid, we performed gene expression profiling with adaptor-tagged competitive PCR, a high-throughput RT-PCR technique.
  • For differential diagnosis, we applied a novel multi-class predictor, introducing probabilistic outputs.
  • CONCLUSION: Molecular diagnosis of thyroid tissues is feasible by gene expression profiling, and the current level is promising towards the automatic diagnostic tool to complement the present medical procedures.
  • [MeSH-major] Bayes Theorem. Gene Expression Profiling. Models, Statistical. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Algorithms. Breast Neoplasms / genetics. Databases, Genetic. Esophageal Neoplasms / genetics. Female. Humans. Kidney Neoplasms / genetics. Leukemia / genetics. Male. Mesothelioma / genetics. Prostatic Neoplasms / genetics. Thyroid Gland / anatomy & histology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene. 2000 Jan 4;241(1):125-31 [10607906.001]
  • [Cites] Bioinformatics. 2005 Nov 15;21(22):4148-54 [16174683.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Diagn Cytopathol. 2002 Jan;26(1):41-4 [11782086.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Genome Biol. 2003;4(3):R21 [12620106.001]
  • [Cites] Bioinformatics. 2003 Jun 12;19(9):1061-9 [12801866.001]
  • [Cites] Bioinformatics. 2003 Jun 12;19(9):1132-9 [12801874.001]
  • [Cites] Bioinformatics. 2003 Nov 1;19(16):2088-96 [14594714.001]
  • [Cites] Bioinformatics. 2004 Oct 12;20(15):2429-37 [15087314.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1978 Nov;86A(6):483-6 [716909.001]
  • [Cites] Tumori. 1993 Oct 31;79(5):314-20 [8116073.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 15;25(22):4694-6 [9358186.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D533-6 [15608255.001]
  • [Cites] Nucleic Acids Res. 2005;33(1):56-65 [15640445.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):422-31 [15659489.001]
  • [Cites] Bioinformatics. 2005 Mar 1;21(5):631-43 [15374862.001]
  • [Cites] Anal Biochem. 2005 Apr 1;339(1):15-28 [15766705.001]
  • [Cites] Bioinformatics. 2005 Jun 1;21(11):2691-7 [15814557.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • (PMID = 16872506.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1550728
  •  go-up   go-down


2. Abbasova SG, Vysotskii MM, Ovchinnikova LK, Obusheva MN, Digaeva MA, Britvin TA, Bahoeva KA, Karabekova ZK, Kazantzeva IA, Mamedov UR, Manuchin IB, Davidov MI: Cancer and soluble FAS. Bull Exp Biol Med; 2009 Oct;148(4):638-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A test system developed by the authors was used to measure serum concentrations of soluble Fas in patients with malignant and benign tumors of different location and morphology.
  • No appreciable differences in the concentrations of soluble Fas were detected in malignant and benign tumors of the mammary gland, bones, ovaries, and adrenals.
  • In thyroid cancer, soluble Fas levels were higher than in benign and hyperplastic processes in this organ.
  • Soluble Fas levels depended on tumor histogenesis in malignant and benign ovarian tumors.
  • High concentration of soluble Fas was detected in large tumors in patients with ovarian cancer, cancer of the corpus uteri, colorectal cancer, thyroid cancer and adenoma, and in adrenocortical cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20396760.001).
  • [ISSN] 1573-8221
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95
  •  go-up   go-down


3. Miyakoshi M, Kamoi K, Takano T, Nishihara M, Kawashima T, Sudo N, Togashi K, Emura I, Williams D: Multiple brown tumors in primary hyperparathyroidism caused by an adenoma mimicking metastatic bone disease with false positive results on computed tomography and Tc-99m sestamibi imaging: MR findings. Endocr J; 2007 Apr;54(2):205-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple brown tumors in primary hyperparathyroidism caused by an adenoma mimicking metastatic bone disease with false positive results on computed tomography and Tc-99m sestamibi imaging: MR findings.
  • We encountered an unusual case of hyperparathyroidism with both hemosiderin deposits on the ribs and low intensity on T2-weighted magnetic resonance imaging (MRI) caused by a parathyroid adenoma with multiple brown tumors that mimicked metastatic bone tumor due to false positive results on computed tomography (CT) and Tc-99m sestamibi (MIBI) imaging.
  • The patient, a middle-aged woman, had very high serum levels of calcium (14.1 mg/dl), alkaline phosphatase (9,369 IU/l) and intact-PTH (12,400 pg/ml), and a large tumor (2.5 cm in diameter) in the lower portion of the left lobe of the thyroid.
  • These findings suggested that the patient had hyperparathyroidism with multiple bone metastases due to carcinoma of the parathyroid gland.
  • However, on pathology, the resected tumor of lower portion of the left lobe of thyroid was diagnosed as a parathyroid adenoma, and the tumors of the left 3rd and 7th ribs, as well as the right 2nd rib, were shown to be brown tumors.
  • It is necessary to determine whether MRI can be used to distinguish between brown tumors and metastases caused by carcinoma of the parathyroid gland.
  • [MeSH-major] Adenoma / diagnosis. Hyperparathyroidism, Primary / etiology. Parathyroid Neoplasms / diagnosis. Radiopharmaceuticals. Ribs. Technetium Tc 99m Sestamibi. Tomography, X-Ray Computed
  • [MeSH-minor] Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Diagnosis, Differential. False Positive Reactions. Female. Hemosiderin / metabolism. Humans. Magnetic Resonance Imaging. Middle Aged. Radionuclide Imaging

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237612.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 9011-92-1 / Hemosiderin; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


Advertisement
4. Aizman A, Larraín S, Rojas L: [Secondary adrenal insufficiency presenting as hyponatremia: report of one case]. Rev Med Chil; 2010 Sep;138(9):1144-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Enfrentamiento de la hiponatremia: Más allá de la corrección del sodio. A propósito de un caso clínico.
  • Thyroid-Stimulating Hormone (TSH) was normal and serum Cortisol < 1 µg/dL.
  • [MeSH-minor] Adenoma / diagnosis. Adrenal Gland Neoplasms / diagnosis. Diabetes Mellitus, Type 2 / complications. Extracellular Space / metabolism. Humans. Hydrocortisone / blood. Inappropriate ADH Syndrome / diagnosis. Male. Middle Aged. Thyrotropin / blood

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21249284.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


5. Tavangar SM, Monajemzadeh M, Larijani B, Haghpanah V: Immunohistochemical study of oestrogen receptors in 351 human thyroid glands. Singapore Med J; 2007 Aug;48(8):744-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study of oestrogen receptors in 351 human thyroid glands.
  • INTRODUCTION: It is well recognised that the pathogenesis of thyroid diseases is complex and different factors such as genetic factors, iodine deficiency, sex, age, radiation therapy in childhood, growth stimulating antibodies, and other epithelial growth factors can influence them.
  • Epidemiological features of thyroid tumours and experimental evidence suggest that female sex hormones may exert effects on the thyroid gland and its neoplasms.
  • This possibility was addressed by investigating the expression of oestrogen receptor protein in 351 thyroid lesions.
  • METHODS: The tissues from 351 human thyroid glands comprising 130 nodular goitres and 221 neoplastic lesions were used for the present immunohistochemical assessment of oestrogen receptor expression.
  • RESULTS: Incidence of oestrogen receptor positive cases were 24 percent (31/130) for nodular goitres, 22 percent (8/37) for follicular adenomas, 11 percent (2/18) for follicular carcinomas, 31 percent (37/119) for papillary carcinomas, zero percent (0/35) for medullary carcinomas and zero percent (0/12) for undifferentiated carcinomas.
  • The incidence of oestrogen receptor positivity, which is compatible with other studies, is higher in well-differentiated thyroid lesions.
  • CONCLUSION: The relatively high proportion of oestrogen receptor positivity in goitres, follicular adenomas and papillary carcinomas, compared with its reactivity in other thyroid neoplasms, and contrasted against normal thyroid tissue, suggests that the incidence of oestrogen receptor reactivity tends to increase with better differentiation of thyroid lesions.
  • [MeSH-major] Goiter / metabolism. Receptors, Estrogen / metabolism. Thyroid Gland / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenoma / metabolism. Adult. Carcinoma, Papillary / metabolism. Female. Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657383.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  •  go-up   go-down


6. Machens A, Dralle H: Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside. Mol Cell Endocrinol; 2006 Mar 9;247(1-2):34-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the initial characterization of the various MEN-2 associated phenotypes (familial medullary thyroid cancer, multiple endocrine neoplasia 2A and 2B) evolved at the bedside, it was at the bench where the underlying RET (REarranged during Transfection) germline mutations were identified.
  • Molecular information has revolutionized our understanding and continues to transform the clinical management of this fascinating endocrine tumor syndrome of neural crest derivation, which consists of medullary thyroid cancer, pheochromocytoma, and parathyroid hyperplasia/adenoma.
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Adrenal Gland Neoplasms / genetics. Adrenal Gland Neoplasms / pathology. Adrenal Medulla / pathology. Age Factors. Animals. Carcinoma, Medullary / genetics. Carcinoma, Medullary / pathology. Genotype. Germ-Line Mutation. Humans. Hyperplasia. Multiple Endocrine Neoplasia Type 2b / genetics. Multiple Endocrine Neoplasia Type 2b / pathology. Neural Crest / pathology. Parathyroid Neoplasms / genetics. Parathyroid Neoplasms / pathology. Phenotype. Pheochromocytoma / genetics. Pheochromocytoma / pathology. Syndrome. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • Genetic Alliance. consumer health - Multiple endocrine neoplasia, type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343738.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-ret
  • [Number-of-references] 58
  •  go-up   go-down


7. Harvey AM, Hibbert A, Barrett EL, Day MJ, Quiggin AV, Brannan RM, Caney SM: Scintigraphic findings in 120 hyperthyroid cats. J Feline Med Surg; 2009 Feb;11(2):96-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to characterise the scintigraphic findings in a large population of hyperthyroid cats in order to determine the location of thyroid pathology in newly diagnosed hyperthyroid cats and those that had previously undergone thyroidectomy.
  • A specific aim was to identify the proportion of cats with ectopic hyperfunctional thyroid tissue and characterise the scintigraphic and clinical features of this subset of cats.
  • Nearly one in five hyperthyroid cats was identified to have multiple areas of hyperfunctional thyroid tissue and/or intrathoracic hyperfunctional thyroid tissue where surgical thyroidectomy would not be curative.
  • In addition, this study demonstrated that scintigraphy cannot reliably distinguish between thyroid carcinoma and adenoma.
  • Owners should always be warned about the possibility of ectopic thyroid tissue before thyroidectomy is performed.
  • In this study, intrathoracic hyperfunctional thyroid tissue and multiple areas of increased radionuclide uptake (IRU) were a common feature of benign thyroid disease and responded well to treatment with low dose radioiodine.
  • [MeSH-minor] Animals. Cats. Choristoma / radionuclide imaging. Choristoma / veterinary. Diagnosis, Differential. Female. Great Britain. Iodine Radioisotopes / administration & dosage. Male. Thyroid Gland. Thyroidectomy / veterinary. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783974.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


8. Pickett CA, Agoff SN, Widman TJ, Bronner MP: Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications. Thyroid; 2005 May;15(5):461-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications.
  • Currently we lack biochemical or molecular markers that predict recurrence and metastases in thyroid cancer.
  • Recent studies in a number of other human malignancies indicate that expression and/or subcellular localization of certain cell cycle regulators has prognostic utility.
  • We have investigated the expression of cyclins D1 and E and of cyclin-dependent kinase inhibitor's p21 and p27 in papillary thyroid cancer (PTC) and correlated this with clinical/histological stage at diagnosis and with clinical outcome.
  • PTCs were compared to normal thyroid, adenomas, and undifferentiated thyroid cancers (UTCs).
  • Our studies indicate that PTCs and UTCs demonstrate low nuclear expression of cyclin E and p27, allowing a clear distinction between adenomas and these carcinomas (p < 0.004).
  • These studies suggest that evaluation of a panel of these markers and attention to their subcellular localization may be a useful adjunct in differentiating benign from malignant thyroid neoplasms and in predicting tumor behavior.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Cell Cycle / physiology. Cyclins / biosynthesis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Cell Cycle Proteins / biosynthesis. Cell Nucleus / pathology. Cyclin D1 / biosynthesis. Cyclin E / biosynthesis. Cyclin-Dependent Kinase Inhibitor p21. Cyclin-Dependent Kinase Inhibitor p27. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Male. Middle Aged. Prognosis. Retrospective Studies. Tissue Fixation. Tumor Suppressor Proteins / biosynthesis


9. Nygaard B, Frisch T, Kiss K: [Thyroid papillary cancer using TPO staining]. Ugeskr Laeger; 2008 Apr 28;170(18):1571
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thyroid papillary cancer using TPO staining].
  • Immunostaining for TPO (MoAb47) has been used to predict the risk of thyroid cancer in thyroid adenomas without uptake in thyroid 99m pertechnetate scintigraphy.
  • This case describes a 16-year-old girl with thyroid papillary cancer staining 95% positive using TPO staining.
  • The case indicates that TPO staining can not be used as the only parameter in the evaluation of the risk of cancer in the thyroid gland.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Papillary / diagnosis. Iodide Peroxidase / analysis. Staining and Labeling / methods. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454932.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


10. Machiavelli GA, Pauni M, Heredia Sereno GM, Szijan I, Basso A, Burdman JA: T3 receptors in human pituitary tumors. Neurol Res; 2009 Nov;31(9):928-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The purpose of this work was to investigate the synthesis of T3 receptors in human tumors of the anterior pituitary gland, its relationship with the hormone synthesized and/or secreted by the tumor and the post-surgical evolution of the patient.
  • METHODS: Patients were evaluated clinically and by magnetic nuclear resonance to classify the adenoma according to their size.
  • DISCUSSION: The presence of thyroid hormone receptors in pituitary tumors is in line with two important characteristics of these tumors: they are histologically benign and well differentiated.
  • [MeSH-major] Adenoma / metabolism. Biomarkers, Tumor / genetics. Pituitary Neoplasms / metabolism. Receptors, Thyroid Hormone / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138463.001).
  • [ISSN] 1743-1328
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Thyroid Hormone; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


11. Aiad HA, Kandil MA, Asaad NY, El-Kased AM, El-Goday SF: Galectin-3 immunostaining in cytological and histopathological diagnosis of thyroid lesions. J Egypt Natl Canc Inst; 2008 Mar;20(1):36-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 immunostaining in cytological and histopathological diagnosis of thyroid lesions.
  • BACKGROUND: Galectin-3 is a human lectin linked to malignant transformation in different organs including thyroid gland.
  • We aimed to evaluate the diagnostic role of galectin-3 in differentiating benign from malignant thyroid lesions in cytological and histological samples.
  • MATERIAL AND METHODS: This study included a total of 79 cases; 19 multinodular goiter (MNG), 19 follicular adenoma (FA), 13 follicular carcinoma (FTC) and 28 papillary carcinoma (PTC).
  • According to H score, glaectin-3 immunostaining was significantly lowered in FA) 1+/-2.8 as compared to papillary (158.5+/-88.6) and follicular carcinoma (150+/-83.9) (p>0.0001).
  • However, there was no statistically significant difference between FTC and PTC (p=0.56) or between classic and follicular variants of PTC (p=0.51).
  • Prospective analysis: There were five benign, six malignant and 17 indeterminate cytology cases.
  • Galectin-3 immunostaining was able to detect the benign nature of 11/17 indeterminate cytology.
  • CONCLUSION: We suggest Galectin-3 as a supplementary immunostaining in histological diagnosis of difficult thyroid follicular lesions and in preoperative evaluation of indeterminate thyroid cytology to avoid unnecessary aggressive surgical interference in benign lesions.
  • [MeSH-major] Galectin 3 / analysis. Goiter, Nodular / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Carcinoma, Papillary / diagnosis. Cytodiagnosis. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847280.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Galectin 3
  •  go-up   go-down


12. Lachinski AJ, Stefaniak T, Kobiela J, Connor S, Gruca Z, Sledzinski Z: New prognostic scales LAST-1 and LAST-2: supporting prediction and staging of thyroid cancer. World J Surg; 2006 Mar;30(3):309-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New prognostic scales LAST-1 and LAST-2: supporting prediction and staging of thyroid cancer.
  • INTRODUCTION: Epidemiologically, thyroid gland tumors are lesions of the highest importance among endocrine tumors in humans.
  • Although the results of surgical treatment of the highly differentiated (follicular and papillary) tumors seem to be satisfactory, treatment of the poorly differentiated (medullary and anaplastic) tumor still demands clinical and basic investigations.
  • In this study the authors sought to evaluate clinical and molecular factors that could contribute to preoperative detection of more advanced thyroid cancers (i.e., those that exhibit extrathyroid spread and lymph node invasion).
  • METHODS: A total of 27 patients operated on for thyroid cancer were evaluated according to age, sex, time from the onset of the disease, cytogenetic changes, and loss of heterozygosity (LOH) in 14 microsatellite markers.
  • The control groups consisted of 25 patients with multinodular goiter (MNG) and 32 patients with follicular adenoma (FA).
  • Based on the multivariate analysis results, two numeric prognostic scales were fashioned: LAST-1, a scale applicable to differentiation of thyroid cancers at different degrees of clinical advancement; and LAST-2, a scale applicable to differentiation of any thyroid lumps.
  • CONCLUSIONS: It was concluded that LOH and the age and sex of the patients can provide sufficient data to predict thyroid cancer with a high degree of clinical advancement.
  • The LAST-2 scale gives supportive information about the character of thyroid lumps, distinguishing TC from MNG and FA.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / pathology. Neoplasm Staging / methods. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3235-40 [10487693.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3684-91 [9360526.001]
  • [Cites] Hum Genet. 1996 Mar;97(3):299-303 [8786068.001]
  • [Cites] Eur J Endocrinol. 2004 Sep;151(3):367-74 [15362967.001]
  • [Cites] Endocr Pathol. 2004 Winter;15(4):319-27 [15681856.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1123-9 [15022277.001]
  • [Cites] Mod Pathol. 2000 May;13(5):562-9 [10824929.001]
  • [Cites] Trends Mol Med. 2004 Jul;10(7):351-7 [15242684.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):271-88 [12665646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Eur J Cancer. 1979 Aug;15(8):1033-41 [510341.001]
  • [Cites] Eur J Cancer. 2001 Dec;37(18):2470-4 [11720845.001]
  • [Cites] Laryngoscope. 2004 Mar;114(3):393-402 [15091208.001]
  • [Cites] Tokai J Exp Clin Med. 2002 Aug;27(2):43-9 [12472169.001]
  • [Cites] Thyroid. 2001 Oct;11(10):953-7 [11716043.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1407-13 [9626044.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3819-24 [14666683.001]
  • [Cites] Ann Surg. 2003 Feb;237(2):227-34 [12560781.001]
  • [Cites] Pathol Res Pract. 2003;199(6):399-404 [12924440.001]
  • [Cites] World J Surg. 2002 Aug;26(8):879-85 [12016468.001]
  • [Cites] Thyroid. 2003 Oct;13(10):949-58 [14611704.001]
  • [Cites] Humangenetik. 1972;15(4):349-53 [4117698.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Apr;52(2):157-64 [2021917.001]
  • [Cites] Lab Invest. 2004 May;84(5):649-57 [15048133.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):58-62 [14736524.001]
  • [Cites] Am Surg. 1995 Feb;61(2):151-5 [7856976.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Dec;26(4):322-8 [10534767.001]
  • [Cites] Wiad Lek. 2004;57(7-8):306-10 [15631182.001]
  • [Cites] Endocr Pathol. 2003 Fall;14(3):213-19 [14586066.001]
  • [Cites] Surgery. 2003 Dec;134(6):1043-7; discussion 1047-8 [14668739.001]
  • [Cites] Surgery. 2002 Apr;131(4):443-9 [11935135.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1234-42 [15085203.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):101-6 [14707871.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] Thyroid. 2001 Dec;11(12):1135-40 [12186500.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4268-72 [11549660.001]
  • [Cites] Ann Genet. 1984;27(3):134-47 [6095729.001]
  • [Cites] Tumori. 2003 Sep-Oct;89(5):517-9 [14870775.001]
  • [Cites] Surgery. 1988 Dec;104(6):947-53 [3194846.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):492-6 [14735198.001]
  • [Cites] Gut. 2004 Dec;53(12):1860-5 [15542529.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8 [7932824.001]
  • [Cites] Curr Treat Options Oncol. 2004 Aug;5(4):315-25 [15233908.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Mar;21(1):79-86 [12071534.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):525-30 [9467569.001]
  • [Cites] Onkologie. 2001 Dec;24(6):561-8 [11799311.001]
  • [Cites] Neoplasma. 2003;50(1):26-30 [12687275.001]
  • [Cites] Cancer Lett. 2004 Jul 16;210(2):151-7 [15183530.001]
  • [Cites] Laryngoscope. 2005 Apr;115(4):661-7 [15805877.001]
  • [Cites] Ear Nose Throat J. 2002 Dec;81(12):856-63 [12516384.001]
  • [Cites] Ann Surg Oncol. 2005 Jan;12(1):81-9 [15827782.001]
  • (PMID = 16479347.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Vorob'ev SL, Zaĭtseva IV, Matveeva ZS: [The informative value of the criteria of cytological diagnostics of tumors of the thyroid gland]. Vestn Khir Im I I Grek; 2007;166(2):62-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The informative value of the criteria of cytological diagnostics of tumors of the thyroid gland].
  • The authors present a comparative analysis of preoperative cytological investigation of 65 bioptates of the thyroid gland obtained by the method of fine-needle aspiration puncture biopsy and smears-prints of the same tumors made during the operation.
  • The degree of correspondence of the cytological and histological investigations was determined in nodular goiter and carcinomas of the thyroid gland.
  • [MeSH-major] Adenoma / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17665579.001).
  • [ISSN] 0042-4625
  • [Journal-full-title] Vestnik khirurgii imeni I. I. Grekova
  • [ISO-abbreviation] Vestn. Khir. Im. I. I. Grek.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


14. Carney JA, Hirokawa M, Lloyd RV, Papotti M, Sebo TJ: Hyalinizing trabecular tumors of the thyroid gland are almost all benign. Am J Surg Pathol; 2008 Dec;32(12):1877-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyalinizing trabecular tumors of the thyroid gland are almost all benign.
  • In 1987, Carney et al reported 11 thyroid tumors with the following features: circumscription or encapsulation, trabecular architecture with intratrabecular hyalin and colloid, polygonal and spindle cells, nuclei with frequent grooves and cytoplasmic inclusions, occasional psammoma bodies, and a low mitotic rate.
  • The neoplasms did not recur or metastasize during a follow-up period that averaged 10 years, and they were titled hyalinizing trabecular adenomas.
  • Later, discovery of RET/PTC mutations in the tumor resulted in it being designated as a type of papillary thyroid carcinoma.
  • We conclude that the overwhelming majority of hyalinizing trabecular tumors of the thyroid behave as benign neoplasms and that, at this time, hyalinizing trabecular adenoma is the most appropriate title for them.
  • [MeSH-major] Adenoma / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813121.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Van den Bruel A, Vauterin T, Poorten VV, Decallonne B: Advances in the medical management of differentiated thyroid carcinoma and their impact on the surgical approach. Acta Chir Belg; 2007 Jun;107(3):271-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the medical management of differentiated thyroid carcinoma and their impact on the surgical approach.
  • The introduction of recombinant human TSH and neck ultrasonography has refined the management of differentiated thyroid cancer, leading to the publication of new guidelines by the American Thyroid Association (ATA) and a consensus report by the European Thyroid Association (ETA) in 2006.
  • In this paper, we give an overview of the current medical management of differentiated thyroid cancer (pre-surgical, post-surgical), of how the advances have been integrated into the recent 2006 ATA guidelines and ETA consensus and finally, of the impact on the surgical management (first surgery, treatment of cervical lymph nodes) of differentiated thyroid cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / surgery. Adenocarcinoma, Papillary / surgery. Adenoma, Oxyphilic / surgery. Lymph Node Excision. Practice Guidelines as Topic. Thyroid Neoplasms / surgery. Thyroidectomy
  • [MeSH-minor] Biopsy, Fine-Needle. Combined Modality Therapy. Consensus. Humans. Iodine Radioisotopes / therapeutic use. Recombinant Proteins / therapeutic use. Thyroid Gland / pathology. Thyrotropin / therapeutic use. Ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17685252.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Recombinant Proteins; 9002-71-5 / Thyrotropin
  • [Number-of-references] 20
  •  go-up   go-down


16. Hoftijzer HC, Liu YY, Morreau H, van Wezel T, Pereira AM, Corssmit EP, Romijn JA, Smit JW: Retinoic acid receptor and retinoid X receptor subtype expression for the differential diagnosis of thyroid neoplasms. Eur J Endocrinol; 2009 Apr;160(4):631-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoic acid receptor and retinoid X receptor subtype expression for the differential diagnosis of thyroid neoplasms.
  • BACKGROUND: Although differential expression of retinoic acid receptor (RAR) subtypes between benign and malignant thyroid tissues has been described, their diagnostic value has not been reported.
  • AIM: To investigate the diagnostic accuracy of RAR and retinoid X receptor (RXR) subtype protein expression for the differential diagnosis of thyroid neoplasms.
  • METHODS: We used a tissue array containing 93 benign thyroid tissues (normal thyroid, multinodular goiter, and follicular adenoma (FA)) and 77 thyroid carcinomas (papillary thyroid carcinoma (PTC), follicular thyroid carcinoma, and follicular variant of PTC (FVPTC)).
  • RESULTS: We found increased expression of cytoplasmic (c) RARA, cRARG, cRXRB and decreased expression of nuclear (n) RARB, nRARG, and nRXRA in thyroid carcinomas compared with benign tissues.
  • Using cluster analysis, the combination of negative staining of membranous RXRB and positive staining for cRXRB had a high positive predictive value (98%) for malignant thyroid disease, whereas the combination of positive nRXRA and negative cRXRB staining had a high predictive value (91%) for benign thyroid lesions.
  • CONCLUSION: We conclude that differences in RAR and RXR subtype protein expression may be valuable for the differential diagnosis of thyroid neoplasms.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155317.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / Retinoid X Receptors
  •  go-up   go-down


17. Ayadi L, Chaâbouni S, Dhouib H, Abbès K, Dhouib M, Makni S, Abdelmoula M, Ghorbel A, Khabir A, Boudawara T: [Polymorphous low-grade adenocarcinoma: about two cases]. Tunis Med; 2009 Jun;87(6):403-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Adénocarcinome polymorphe de bas grade: à propos de deux cas.
  • AIM: Our aim is to discuss morphology, evolution and differential diagnosis of this rare tumour.
  • A biopsy concluded to a pleomorphic adenoma.
  • Giving that the mass enlarged, a surgical resection carrying off the thyroid with a bilateral neck dissection was performed.
  • Diagnosis was an APBG partially resected with lymph node metastasis.
  • CONCLUSION: APBG is characterised by a morphologic diversity and a cytologic uniformity that may cause a diagnostic dilemma especially with adenoid cystic carcinoma and pleomorphic adenoma.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor


18. Szepietowska B, Myśliwiec J, Telejko B: [Subacute thyroiditis in woman presenting with thyrotropin-secreting pituitary adenoma]. Pol Arch Med Wewn; 2005 Apr;113(4):364-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Subacute thyroiditis in woman presenting with thyrotropin-secreting pituitary adenoma].
  • Thus, it is very rare tumor of this endocrine gland.
  • Standards of the diagnosis of TSH-omas are based on me lack of inhibition of TSH levels in the presence of increased free thyroid hormones and abnormal, neoplastic intrasellar or parasellar mass.
  • [MeSH-major] Adenoma / complications. Pituitary Neoplasms / complications. Thyroiditis, Subacute / etiology. Thyrotropin / blood. Thyrotropin / secretion
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16209252.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin
  •  go-up   go-down


19. Wu Z, Zhou Q, Wang DJ: An intracardiac ectopic thyroid adenoma. Interact Cardiovasc Thorac Surg; 2009 May;8(5):587-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An intracardiac ectopic thyroid adenoma.
  • Intracardiac ectopic thyroid tissue is a rare lesion.
  • We present a case of successful excision of an ectopic thyroid adenoma originated from the right ventricular aspect of the interventricular septum and extending to the right ventricular outflow tract.
  • The 12-month follow-up shows normal thyroid function and good clinical status of the patient.
  • In our estimation, there was no case with an intracardiac ectopic thyroid adenoma reported before in China.
  • [MeSH-major] Adenoma / surgery. Cardiac Surgical Procedures. Choristoma. Heart Neoplasms / surgery. Thyroid Gland. Thyroid Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Heart Surgery.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208659.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Máximo V, Botelho T, Moreira S, Meireles AM, Magalhães J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simões M: Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch; 2005 Jun;446(6):589-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness.
  • A high prevalence of the BRAF(V600E) somatic mutation was recently reported in several series of papillary thyroid carcinomas (PTC).
  • Another BRAF mutation (K601E) was detected in a follicular adenoma and in some cases of the follicular variant of PTC.
  • The BRAF(V600E) mutation was exclusively detected in PTC with a papillary or mixed follicular/papillary architecture both of the conventional type (46%) and of other histotypes, such as microcarcinoma (43%), Warthin-like PTC (75%) and oncocytic variant of PTC (55%).
  • The BRAF(K601E) mutation was detected in four of the 54 cases of the follicular variant of PTC (7%).
  • The BRAF (BRAF(V600E)) mutated PTC did not exhibit signs of higher aggressiveness (size, vascular invasion, extra-thyroid extension and nodal metastasis) and were in fact less often multicentric than PTC without the mutation.
  • [MeSH-major] Carcinoma, Papillary / genetics. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adult. Age Factors. Carcinoma, Papillary, Follicular / genetics. DNA Mutational Analysis. Humans. Male. Middle Aged. Mutation. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Sex Factors

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pathol. 2002 Winter;13(4):289-99 [12665647.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):572-6 [15095090.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] Yonsei Med J. 2004 Oct 31;45(5):818-21 [15515191.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):287-94 [9516913.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):878-82 [10690905.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):934 [12198537.001]
  • [Cites] Cancer Lett. 2004 Jun 8;209(1):1-6 [15145515.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] Semin Diagn Pathol. 1985 May;2(2):90-100 [3843693.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2414-20 [15126572.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4561-7 [12907632.001]
  • [Cites] J Pathol. 1998 May;185(1):71-8 [9713362.001]
  • [Cites] Biol Cell. 2001 Sep;93(1-2):53-62 [11730323.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 [12697856.001]
  • [Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):313-20 [12665649.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Mar;128(3):237-40 [11886336.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4393-7 [12970315.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4267-71 [15356020.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):342-8 [15009715.001]
  • (PMID = 15902486.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


21. Oka Y, Nishijima J, Azuma T, Inada K, Miyazaki S, Nakano H, Nishida Y, Sakata K, Hashimoto J, Izukura M: Blunt thyroid trauma with acute hemorrhage and respiratory distress. J Emerg Med; 2007 May;32(4):381-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blunt thyroid trauma with acute hemorrhage and respiratory distress.
  • We report a rare event of acute hemorrhage into a thyroid adenoma after blunt trauma and causing respiratory distress.
  • Computed tomography and magnetic resonance imaging revealed significant tracheal deviation to the right due to an extensive hematoma surrounded by a capsule in the left lobe of the thyroid gland with extension to the upper mediastinum.
  • The patient was referred to our hospital because the diagnosis of malignant thyroid tumor was not completely ruled out.
  • She successfully underwent left lobectomy of the thyroid gland without sternotomy.
  • The pathological examination revealed follicular adenoma of the thyroid gland with massive intratumor bleeding.
  • [MeSH-major] Adenoma / complications. Hemorrhage / etiology. Thyroid Gland / injuries. Thyroid Gland / pathology. Thyroid Neoplasms / complications. Wounds, Nonpenetrating / complications

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17499691.001).
  • [ISSN] 0736-4679
  • [Journal-full-title] The Journal of emergency medicine
  • [ISO-abbreviation] J Emerg Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Sheu SY, Vogel E, Worm K, Grabellus F, Schwertheim S, Schmid KW: Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma. Histopathology; 2010 Apr;56(5):632-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma.
  • AIMS: To compare the expression pattern of five microRNAs (miRNAs) (146b, -181b, -21, -221, -222) of papillary thyroid carcinoma (PTC) and hyalinizing trabecular tumour of the thyroid (HTT).
  • METHODS AND RESULTS: The expression pattern of five miRNAs known to be up-regulated in PTC was retrospectively analysed in 18 HTTs, adjacent normal thyroid tissue, 10 PTCs, 10 follicular adenomas and 10 non-toxic multinodular goitres (MNG) by reverse transcriptase-polymerase chain reaction using the TaqMan miRNA assay.
  • All miRNAs were significantly up-regulated in PTCs, whereas all miRNAs in HTT, normal thyroid tissue, adenomas, and MNGs were down-regulated.
  • It is suggested that HTTs lacking both a miRNA expression pattern characteristic for PTC and RET/PTC rearrangements are re-designated as 'hyalinizing trabecular adenomas'.
  • [MeSH-major] Adenocarcinoma, Papillary / genetics. Adenoma / genetics. MicroRNAs / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Gene Rearrangement. Goiter, Nodular / genetics. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Humans. Hyalin / metabolism. Mutation. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / metabolism. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins B-raf / metabolism. Retrospective Studies. Thyroid Gland / metabolism. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459574.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Oncogene Proteins, Fusion; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / ret-PTC fusion oncoproteins, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


23. Rivolta CM, Moya CM, Esperante SA, Gutnisky VJ, Varela V, Targovnik HM: [The thyroid as a model for molecular mechanisms in genetic diseases]. Medicina (B Aires); 2005;65(3):257-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The thyroid as a model for molecular mechanisms in genetic diseases].
  • [Transliterated title] La tiroides como modelo de mecanismos moleculares en enfermedades geneticas.
  • Thyroid diseases constitute a heterogeneous collection of abnormalities associated with mutations in genes responsible for the development of thyroid: thyroid transcription factor-1 (TTF-1), thyroid transcriptions factor-2 (TTF-2) and PAX8, or in one of the genes coding for the proteins involved in thyroid hormone biosynthesis such as thyroglobulin (TG), thyroperoxidase (TPO), hydrogen peroxide-generating system (DUOX2), sodium/iodide symporter (NIS), pendrin (PDS), TSH and TSH receptor (TSHr).
  • Somatic mutations of the TSHr have been identified in hyperfunctioning thyroid adenomas.
  • Another established thyroid disease is the resistance to thyroid hormone (RTH).
  • It is a syndrome of reduced tissue responsiveness to hormonal action caused by mutations located in the thyroid hormone receptor beta (TRbeta) gene.
  • In conclusion, the identification of mutations in the thyroid expression genes has provided important insights into structure-function relationships.
  • The thyroid constitutes an excellent model for the molecular study of genetic diseases.
  • [MeSH-minor] Humans. Iodide Peroxidase / genetics. Iodide Peroxidase / metabolism. Mutation. Receptors, Thyrotropin / genetics. Thyroid Hormones / biosynthesis. Thyroid Hormones / genetics

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16042141.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Receptors, Thyrotropin; 0 / Thyroid Hormones; EC 1.11.1.8 / Iodide Peroxidase
  • [Number-of-references] 106
  •  go-up   go-down


24. Magro G, Benkova K, Michal M: Meningioma-like tumor of the thyroid: a previously undescribed variant of follicular adenoma. Virchows Arch; 2005 Jun;446(6):677-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma-like tumor of the thyroid: a previously undescribed variant of follicular adenoma.
  • [MeSH-major] Adenoma / pathology. Meningioma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Clin Path. 2000 Jan;4(1):35-9 [10936897.001]
  • [Cites] AMA Arch Pathol. 1954 Dec;58(6):554-63 [13217570.001]
  • [Cites] Endocr Pract. 2001 Sep-Oct;7(5):370-4 [11585373.001]
  • [Cites] Virchows Arch. 2005 Jan;446(1):91-2 [15517364.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):199-204 [11863215.001]
  • (PMID = 15891903.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Das K, Kendall C, Isabelle M, Fowler C, Christie-Brown J, Stone N: FTIR of touch imprint cytology: a novel tissue diagnostic technique. J Photochem Photobiol B; 2008 Sep 18;92(3):160-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FTIR spectral profiles of TIC of lymph node and thyroid tissues differ visually when compared with TIC spectra of parathyroid tissue.
  • The thyroid spectra, in addition to evident strong protein peaks at 1547cm(-1) and 1659cm(-1), also demonstrated possible nucleic acid signals at 1079cm(-1) and 1244cm(-1).
  • Parathyroid adenoma showed a marginal shift to lower wavenumbers with decreased amide I and II peak intensities when compared to hyperplasia.
  • Nucleic acid peak positions at 1079cm(-1) and 1244cm(-1) were of higher intensity in adenomas compared to hyperplastic glands possibly demonstrating an increase in cell proliferation and growth.
  • This study demonstrates the feasibility of cytoimprint FTIR for the intraoperative diagnosis of tissue during surgical neck exploration for the management of hyperparathyroidism.
  • There is potential for the application of the technique in sentinel lymph node biopsy diagnosis and tumour margin evaluation.
  • [MeSH-minor] Adenoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Frozen Sections. Hyperparathyroidism / surgery. Lymph Node Excision. Parathyroid Neoplasms / surgery. Thyroid Gland / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18640848.001).
  • [ISSN] 1011-1344
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / CSA/03/07/017
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


26. Eszlinger M, Paschke R: Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol; 2010 Jun 30;322(1-2):29-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns.
  • Fine-needle aspiration biopsy (FNAB) is currently the most sensitive and specific tool for the presurgical differential diagnosis of thyroid malignancy, but has also substantial limitations.
  • While approximately 75% of FNAB reveal benign lesions and 5% already cytologically prove malignancy, up to 20% of FNAB show follicular proliferation for which follicular adenoma, follicular carcinoma, and follicular variant of papillary carcinoma can only be distinguished histologically, thus requiring thyroid surgery.
  • However, new biomarkers that might improve the accuracy of FNAB come along with the discovery of more and more details of the molecular etiology of thyroid tumors.
  • Nevertheless, the application of molecular markers will significantly improve thyroid tumor diagnosis and thus it will help to prevent unnecessary surgeries and it will also help to guide mutation-specific targeted therapies.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis. Thyroid Nodule / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biopsy, Fine-Needle. Diagnosis, Differential. Gene Expression Profiling. Humans. Mutation

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20083161.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 123
  •  go-up   go-down


27. Mofid AR, Yazdani T, Shahrzad M, Seyedalinaghi S, Zandieh S: Role of fine-needle aspiration in the management of thyroid nodules. Saudi Med J; 2009 Apr;30(4):515-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of fine-needle aspiration in the management of thyroid nodules.
  • OBJECTIVE: To show the benefits of fine-needle aspiration biopsy (FNAB) in managing thyroid nodules.
  • METHODS: As a retrospective study, reports of 888 FNABs of the thyroid performed during a period of 11 years (1996-2007) at Tehran University of Medical Sciences, Sina Hospital and Endocrine Clinic, Tehran, Iran were reviewed.
  • RESULTS: The cytology diagnoses by FNAB were: papillary 6 (3.2%); follicular neoplasm 51 (28%); follicular adenoma 10 (5.4%); Hurthle cell neoplasm 8 (4.3%); suspicious 20 (10.9%); inconclusive 2 (1%); and benign 85 (46.4%).
  • Due to surgery pathologic reports, malignant cytologies were: 6 (100%) for papillary, 1 (1.96%) for follicular neoplasm, 4 (50%) for Hurthle cell neoplasm.
  • CONCLUSION: Fine needle aspiration is a useful technique for selecting patients with nodular thyroid disease for surgery.
  • [MeSH-major] Goiter, Nodular / pathology. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19370278.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


28. Espiritu RP, Dean DS: Parathyroidectomy-induced thyroiditis. Endocr Pract; 2010 Jul-Aug;16(4):656-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In 2 women (84 years old and 55 years old) with no history of thyroid disease in one of them and a remote history of excision of a follicular adenoma in the other, thyrotoxicosis developed a few days to a week after parathyroidectomy for primary hyperparathyroidism.
  • The first patient underwent bilateral cervical exploration with removal of a right inferior parathyroid adenoma, whereas the second patient had excision of 3 1/2 parathyroid glands for 4-gland hyperplasia and 2 benign nodules from the left thyroid lobe.
  • Laboratory results showed elevated levels of free thyroxine, suppressed thyroid-stimulating hormone levels, very low radioiodine uptake (in the second patient), and an elevated thyroglobulin level (in the first patient).
  • Thyroid function normalized and symptoms diminished after 1 to 2 months.
  • Candidates for parathyroidectomy should be informed of this potential complication, and thyroid function should be assessed if clinically indicated.
  • [MeSH-minor] Adrenergic beta-Antagonists / therapeutic use. Aged, 80 and over. Female. Humans. Hyperparathyroidism, Primary / surgery. Middle Aged. Postoperative Period. Thyroid Function Tests. Thyrotoxicosis / blood. Thyrotoxicosis / drug therapy. Thyrotoxicosis / epidemiology. Thyrotoxicosis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350919.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists
  •  go-up   go-down


29. Murakami S, Sakata H, Okubo K, Tsuji Y, Kayano H: Thyroid adenoma with extensive extracellular mucin deposition: report of a case. Surg Today; 2007;37(3):226-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid adenoma with extensive extracellular mucin deposition: report of a case.
  • A thyroid tumor with extensive extracellular mucin deposition is extremely rare.
  • We herein describe a case of a thyroid adenoma with prominent myxoid stroma.
  • Radiological examinations showed this mass to be a thyroid tumor with a cystic component.
  • [MeSH-major] Adenoma / pathology. Mucins / analysis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for thyroid adenoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thyroid. 1997 Oct;7(5):725-31 [9349575.001]
  • [Cites] Acta Pathol Jpn. 1992 Feb;42(2):111-4 [1314005.001]
  • [Cites] Cancer. 1985 Dec 1;56(11):2647-50 [2996743.001]
  • [Cites] Histopathology. 1984 Sep;8(5):847-60 [6083973.001]
  • [Cites] Am J Surg Pathol. 1985 Sep;9(9):619-29 [2996373.001]
  • [Cites] Cancer. 1976 Sep;38(3):1323-5 [182353.001]
  • [Cites] J Clin Pathol. 1985 Mar;38(3):277-80 [3973051.001]
  • [Cites] Histopathology. 2003 May;42(5):514-6 [12713633.001]
  • [Cites] J Oral Pathol. 1986 Nov;15(10):518-9 [3104557.001]
  • [Cites] J Clin Pathol. 1996 Dec;49(12):1015-7 [9038743.001]
  • [Cites] Hum Pathol. 1995 Oct;26(10):1099-108 [7557943.001]
  • [Cites] Thyroid. 1999 Apr;9(4):401-4 [10319948.001]
  • [Cites] Jpn J Clin Oncol. 1984 Sep;14(3):417-24 [6482020.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):195-200 [3277907.001]
  • [Cites] Pathol Res Pract. 1993 Jun;189(5):608-12; discussion 612-5 [8397391.001]
  • [Cites] J Pathol. 1991 Jul;164(3):261-3 [1679843.001]
  • [Cites] Arch Anat Cytol Pathol. 1990;38(3):114-6 [2363591.001]
  • [Cites] Cancer. 1990 May 1;65(9):2020-7 [1695544.001]
  • [Cites] Am J Surg Pathol. 1984 Sep;8(9):705-8 [6383090.001]
  • [Cites] Histopathology. 1987 Mar;11(3):317-26 [3428884.001]
  • [Cites] J Clin Pathol. 1987 Aug;40(8):890-5 [3654988.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):551-6 [12354139.001]
  • [Cites] Cancer. 1980 May 15;45(10):2564-7 [6247054.001]
  • [Cites] Arch Pathol Lab Med. 2000 Oct;124(10 ):1547-52 [11035596.001]
  • [Cites] Arch Pathol Lab Med. 1983 Feb;107(2):70-4 [6687422.001]
  • [Cites] Int J Gynecol Pathol. 1996 Apr;15(2):137-45 [8786203.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):698-701 [16021578.001]
  • [Cites] Cytopathology. 2000 Jun;11(3):185-90 [10877279.001]
  • [Cites] Acta Pathol Jpn. 1987 Jul;37(7):1157-64 [2821736.001]
  • [Cites] Cancer. 1977 Jan;39(1):210-4 [832236.001]
  • (PMID = 17342362.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Mucins
  • [Number-of-references] 32
  •  go-up   go-down


30. Cardenas MG, Kini S, Wisgerhof M: Two patients with highly aggressive macrofollicular variant of papillary thyroid carcinoma. Thyroid; 2009 Apr;19(4):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two patients with highly aggressive macrofollicular variant of papillary thyroid carcinoma.
  • BACKGROUND: The macrofollicular variant of papillary thyroid carcinoma (MFV-PTC) is an unusual type of thyroid carcinoma with histological features that can be confused with nodular goiter or follicular adenoma.
  • SUMMARY: The first patient was a 59-year-old woman with an occipital mass diagnosed histologically as papillary thyroid carcinoma (PTC), follicular variant.
  • Ten years earlier a biopsy of a thyroid nodule had been negative for malignant cells.
  • Thyroidectomy showed a 3-cm nodule in the thyroid, diagnosed as MFV-PTC.
  • The second patient was an 81-year-old man with a history of right thyroid nodule treated by total thyroidectomy with a postoperative diagnosis of adenomatous goiter.
  • Three years later he developed a right shoulder mass, histologically diagnosed as follicular variant of PTC.
  • He died of metastatic thyroid cancer.
  • Although MFV-PTC usually has a good prognosis these cases highlight the importance of careful histopathological examination for MFV-PTC in thyroidectomy specimens that may appear to be seemingly benign nodular thyroid disease.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Bone Neoplasms / secondary. Carcinoma, Papillary / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Fatal Outcome. Female. Humans. Male. Middle Aged. Thyroid Nodule / diagnosis. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19355832.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Montone KT, Baloch ZW, LiVolsi VA: The thyroid Hürthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review. Arch Pathol Lab Med; 2008 Aug;132(8):1241-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The thyroid Hürthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review.
  • CONTEXT: Hürthle cells are eosinophilic, follicular-derived cells that are associated with a variety of nonneoplastic and neoplastic thyroid lesions.
  • The differential diagnosis of Hürthle cell lesions is quite broad.
  • OBJECTIVE: To review the pathologic conditions associated with Hürthle cells in the thyroid and to discuss pathology of thyroid lesions associated with oncocytic cytology.
  • DATA SOURCES: A variety of thyroid nonneoplastic (autoimmune thyroiditis, multinodular goiter) and neoplastic conditions (Hürthle cell adenoma, Hürthle cell carcinoma) are associated with Hürthle cell cytology.
  • In addition, there are several thyroid neoplasms that should be considered when one observes a Hürthle cell neoplasm in the thyroid (oncocytic variant of medullary carcinoma, several variants of papillary thyroid carcinoma).
  • CONCLUSIONS: Oncocytic cytology is seen in a variety of thyroid conditions that are associated with a broad differential diagnosis and care must be used for accurate diagnosis.
  • Newer molecular-based techniques may be useful for further classification of thyroid neoplasms with oncocytic pathology.
  • [MeSH-major] Oxyphil Cells / pathology. Thyroid Diseases / pathology. Thyroid Gland / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Biopsy, Needle. Diagnosis, Differential. History, 19th Century. Humans. Metaplasia. Pathology, Surgical / methods. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Thyroid Conditions.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684023.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 107
  •  go-up   go-down


32. Uchida N, Suda T, Inoue T, Fujiwara Y, Ishiguro K: Needle track dissemination of follicular thyroid carcinoma following fine-needle aspiration biopsy: report of a case. Surg Today; 2007;37(1):34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Needle track dissemination of follicular thyroid carcinoma following fine-needle aspiration biopsy: report of a case.
  • Few reports have been concerned with the risk of needle track dissemination of tumor cells following fine-needle aspiration biopsy, especially for follicular thyroid nodules.
  • A 61-year-old woman who underwent fine-needle aspiration biopsy and surgery 5 years previously for follicular thyroid adenoma presented with nodules that had developed in the sternocleidomastoid and omohyoid muscles of the anterior neck.
  • These nodules were located along a line from the skin to the thyroid that coincided with the needle track of the previous biopsy.
  • Following surgical resection, histological diagnosis determined the nodules to be follicular carcinoma.
  • Although fine-needle aspiration biopsy is a useful tool for the diagnosis of thyroid nodules, it is important to consider the risk of tumor cell dissemination.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Biopsy, Fine-Needle / adverse effects. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Seeding. Thyroid Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Thyroid Gland / pathology. Ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2005 Dec;29(12):1544-9 [16311845.001]
  • [Cites] N Engl J Med. 1989 Mar 30;320(13):835-40 [2927450.001]
  • [Cites] Radiology. 1991 Jan;178(1):253-8 [1984314.001]
  • [Cites] Acta Radiol. 2000 Sep;41(5):435-40 [11016762.001]
  • [Cites] Acta Cytol. 2002 May-Jun;46(3):591-5 [12040660.001]
  • [Cites] Monogr Pathol. 1993;(35):166-99 [8502250.001]
  • [Cites] Thyroid. 1994 Fall;4(3):319-26 [7833670.001]
  • [Cites] Mod Pathol. 1996 Jun;9(6):710-5 [8782212.001]
  • [Cites] Am J Surg. 2000 Aug;180(2):104-7 [11044522.001]
  • [Cites] Diagn Cytopathol. 1994;10(2):156-8 [8187596.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] J Surg Oncol. 1995 Mar;58(3):168-72 [7898112.001]
  • [Cites] ANZ J Surg. 2003 Jul;73(7):480-3 [12864820.001]
  • [Cites] Acta Cytol. 1990 Nov-Dec;34(6):801-4 [2256415.001]
  • [Cites] Curr Treat Options Oncol. 2002 Aug;3(4):349-54 [12074771.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Mar;83(3):780-3 [9506726.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):505-24 [11169933.001]
  • [Cites] J Clin Pathol. 1998 Mar;51(3):241-3 [9659269.001]
  • (PMID = 17186343.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Smayra T, Abi Khalil S, Abboud B, Halabi G, Slaba S: [Unusual location of a parathyroid adenoma: the carotid sheath]. J Radiol; 2006 Jan;87(1):59-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual location of a parathyroid adenoma: the carotid sheath].
  • [Transliterated title] Localisation atypique d'un adénome parathyroïdien: la gaine carotidienne.
  • We report the imaging features of an occult parathyroid adenoma with unusual location in the carotid sheath.
  • Digital angiography showed a tumoral blush supplied by the left inferior thyroid artery and located in close contact with the carotid artery.
  • Venous sampling of the neck confirmed the left location of the adenoma and a third surgical intervention found the adenoma embedded in the left carotid sheath.
  • This is an unusual case of parathyroid adenoma that necessitated the use of several imaging techniques.
  • [MeSH-major] Adenoma / diagnosis. Carotid Artery, Common / pathology. Parathyroid Neoplasms / diagnosis. Vascular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Angiography, Digital Subtraction. Female. Humans. Hyperparathyroidism / diagnosis. Magnetic Resonance Imaging. Neck Dissection. Thyroid Gland / blood supply. Thyroidectomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16415782.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


34. Zhou GW, Wei Y, Chen X, Jiang XH, Li XY, Ning G, Li HW: Diagnosis and surgical treatment of multiple endocrine neoplasia. Chin Med J (Engl); 2009 Jul 5;122(13):1495-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and surgical treatment of multiple endocrine neoplasia.
  • We discuss the diagnosis and surgical treatment of MEN.
  • There were 22 cases of primary hyperparathyroidism (PHPT), 10 cases of enteropanceatic tumor including 9 cases of insulinoma, 15 cases of pituitary adenoma, 9 cases of adrenal adenoma, 2 cases of thymic carcinoid.
  • Two patients had 4 glands involved, 3 patients had 3 glands involved, 16 patients had 2 glands involved, and 6 patients had only one gland involved.
  • 48 cases of MEN2a had thyroid masses with elevated calcitonin levels.
  • 5 MEN2b patients had medullary thyroid carcinoma and mucosal ganglioneuromatosis with Marfanoid.
  • RESULTS: In MEN1, subtotal parathyroidectomy was performed in 12 patients with PHPT and one patient received parathyroid adenoma enucleation.
  • Germline mutation test is helpful in establishing a diagnosis.

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19719936.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Codon; 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human
  •  go-up   go-down


35. Horányi J, Duffek L, Kemenes M, Szlávik R, Darvas K, Dabasi G, Lakatos P, Tóth M: [New intraoperative diagnostic methods parathyroid surgery. Adenoma localization by gamma probe]. Orv Hetil; 2005 Jul 3;146(27):1443-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New intraoperative diagnostic methods parathyroid surgery. Adenoma localization by gamma probe].
  • [Transliterated title] Uj, intraoperatív diagnosztikus módszerek a mellékpajzsmirigy-sebészetben: gamma-szondás adenoma-lokalizáció.
  • INTRODUCTION: The key to heal primary hyperparathyroidism is to find the hyper functioning parathyroid gland(s).
  • METHODS: At 122 patients undergoing parathyroidectomy in last 5 years with diagnosis of primary hyperparathyroidism perioperative sestamibi scanning by gamma probe was taken to localize the adenoma.
  • RESULTS: Because of the thyroid lobes also accumulate sestamibi the localizability of adenomas depended on direction of scanning.
  • Localization of adenomas by percutaneous measurement was correct in 36.1% of cases and by perioperative direct scanning in 66.4%.
  • Furthermore, ex vivo scan of removed adenomas showed impressively high activity in all cases.
  • CONCLUSIONS: In their experience sestamibi scanning lightens the operation only in a part of cases but probably it will be the most important method of localization if isotope selectively accumulating in parathyroid gland could be found.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / surgery. Gamma Rays. Parathyroid Diseases / diagnosis. Parathyroid Diseases / surgery. Parathyroidectomy

  • MedlinePlus Health Information. consumer health - Parathyroid Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16089105.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


36. Zhou C, Wang Y, Aguirre AD, Tsai TH, Cohen DW, Connolly JL, Fujimoto JG: Ex vivo imaging of human thyroid pathology using integrated optical coherence tomography and optical coherence microscopy. J Biomed Opt; 2010 Jan-Feb;15(1):016001
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex vivo imaging of human thyroid pathology using integrated optical coherence tomography and optical coherence microscopy.
  • We evaluate the feasibility of optical coherence tomography (OCT) and optical coherence microscopy (OCM) for imaging of benign and malignant thyroid lesions ex vivo using intrinsic optical contrast.
  • 34 thyroid gland specimens are imaged from 17 patients, covering a spectrum of pathology ranging from normal thyroid to benign disease/neoplasms (multinodular colloid goiter, Hashimoto's thyroiditis, and follicular adenoma) and malignant thyroid tumors (papillary carcinoma and medullary carcinoma).
  • Characteristic features that suggest malignant lesions, such as complex papillary architecture, microfollicules, psammomatous calcifications, or replacement of normal follicular architecture with sheets/nests of tumor cells, can be identified from OCT and OCM images and are clearly differentiable from normal or benign thyroid tissues.
  • With further development of needle-based imaging probes, OCT and OCM could be promising techniques to use for the screening of thyroid nodules and to improve the diagnostic specificity of fine needle aspiration evaluation.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):474-9 [10744825.001]
  • [Cites] Opt Express. 2009 Jan 19;17(2):784-96 [19158891.001]
  • [Cites] Endoscopy. 2000 Dec;32(12):921-30 [11147939.001]
  • [Cites] AJR Am J Roentgenol. 2002 Mar;178(3):687-91 [11856699.001]
  • [Cites] J Endocrinol Invest. 2002 Jan;25(1):39-43 [11885575.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):1941-6 [11994321.001]
  • [Cites] Head Neck. 2002 Jul;24(7):651-5 [12112538.001]
  • [Cites] J Ultrasound Med. 2003 Feb;22(2):127-31; quiz 132-4 [12562117.001]
  • [Cites] Lancet. 2003 Feb 8;361(9356):501-11 [12583960.001]
  • [Cites] Opt Lett. 2003 Nov 1;28(21):2064-6 [14587816.001]
  • [Cites] J Ultrasound Med. 2003 Oct;22(10):1027-31 [14606557.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):85-97 [14999139.001]
  • [Cites] Head Neck. 2004 May;26(5):425-34 [15122659.001]
  • [Cites] J Ultrasound Med. 2004 Nov;23(11):1455-64 [15498910.001]
  • [Cites] AJR Am J Roentgenol. 1982 Mar;138(3):499-501 [6978000.001]
  • [Cites] Radiology. 1991 Dec;181(3):683-7 [1947082.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1178-81 [1957169.001]
  • [Cites] J Ultrasound Med. 1994 Feb;13(2):87-90 [7932966.001]
  • [Cites] Ir J Med Sci. 1994 Oct;163(10):451-4 [7814246.001]
  • [Cites] J Urol. 1997 May;157(5):1915-9 [9112562.001]
  • [Cites] Science. 1997 Jun 27;276(5321):2037-9 [9197265.001]
  • [Cites] Am J Gastroenterol. 1997 Oct;92(10):1800-4 [9382040.001]
  • [Cites] Dig Dis Sci. 1998 Jun;43(6):1193-9 [9635607.001]
  • [Cites] J Ultrasound Med. 1998 Aug;17(8):487-96 [9697951.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):561-74 [16185971.001]
  • [Cites] Ultrasound Med Biol. 2005 Oct;31(10):1343-9 [16223637.001]
  • [Cites] Nat Methods. 2005 Dec;2(12):941-50 [16299479.001]
  • [Cites] Radiology. 2005 Dec;237(3):794-800 [16304103.001]
  • [Cites] Diagn Cytopathol. 2006 Jan;34(1):67-76 [16355378.001]
  • [Cites] Opt Lett. 2006 Apr 15;31(8):1076-8 [16625908.001]
  • [Cites] Thyroid. 2006 Feb;16(2):109-42 [16420177.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] Opt Lett. 2006 Oct 15;31(20):2975-7 [17001371.001]
  • [Cites] J Biomed Opt. 2006 Sep-Oct;11(5):054015 [17092164.001]
  • [Cites] Endoscopy. 2007 Jul;39(7):599-605 [17611914.001]
  • [Cites] Opt Lett. 2007 Jul 15;32(14):1971-3 [17632613.001]
  • [Cites] Radiology. 2007 Sep;244(3):865-74 [17630358.001]
  • [Cites] Gastrointest Endosc. 2007 Nov;66(5):1001-7 [17767932.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jan;6(1):95-101 [18065276.001]
  • [Cites] Radiology. 2008 Jun;247(3):762-70 [18403624.001]
  • [Cites] Urology. 2000 May;55(5):783-7 [10792101.001]
  • (PMID = 20210448.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075289-14; United States / NCI NIH HHS / CA / R01 CA075289; United States / NCI NIH HHS / CA / R01 CA075289-14; United States / NCI NIH HHS / CA / R01-CA75289-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2844129
  •  go-up   go-down


37. Matesa N, Samija I, Kusić Z: Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions. Cytopathology; 2007 Apr;18(2):112-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions.
  • OBJECTIVE: To investigate whether the presence of macrophages and Hürthle cells (HC) in benign thyroid lesions could explain the false-positive expression of galectin-3 and CD44v6 detected by reverse transcriptase-polymerase chain reaction (RT-PCR).
  • METHODS: For galectin-3 and CD44v6, RT-PCR was performed on RNA isolated from aspirates obtained by ultrasound guided fine needle aspiration cytology (FNAC) from 123 patients with benign thyroid lesions.
  • The results of RT-PCR analysis were evaluated against the definitive FNAC diagnosis.
  • RESULTS: Galectin-3 expression was found in 29% follicular adenoma (FA), 26% Hashimoto thyroiditis (HT), and in 24% nodular goitre (NG).
  • [MeSH-major] Antigens, CD44 / metabolism. Biomarkers / metabolism. Biopsy, Fine-Needle. Cell Adhesion. Galectin 3 / metabolism. Glycoproteins / metabolism. Thyroid Diseases / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. False Positive Reactions. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Hashimoto Disease / metabolism. Hashimoto Disease / pathology. Humans. Macrophages / metabolism. Macrophages / pathology. Oxyphil Cells / metabolism. Oxyphil Cells / pathology. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17397496.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers; 0 / CD44v6 antigen; 0 / Galectin 3; 0 / Glycoproteins; 0 / RNA, Messenger
  •  go-up   go-down


38. Gates JD, Benavides LC, Shriver CD, Peoples GE, Stojadinovic A: Preoperative thyroid ultrasound in all patients undergoing parathyroidectomy? J Surg Res; 2009 Aug;155(2):254-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative thyroid ultrasound in all patients undergoing parathyroidectomy?
  • BACKGROUND: Coexisting thyroid nodules are the most common cause of false positive localization by radioscintigraphy in the preoperative evaluation for MIPS in patients with primary hyperparathyroidism (pHPT).
  • This false positive finding can prompt full neck exploration in the setting of an unanticipated and incompletely evaluated thyroid nodule.
  • Therefore, we are studying prospectively the routine use of preoperative thyroid US in patients with pHPT to determine the prevalence of concurrent thyroid disease and to assess how frequently this added information could alter the surgical plan.
  • MATERIALS AND METHODS: Twenty-four patients with biochemically confirmed pHPT were evaluated with thyroid US after localizing (99m)Tc-sestamibi scintigraphy prior to parathyroid operation.
  • RESULTS: Of the 24 patients, 38% (n = 9) had their operations altered from a planned MIPS or four-gland exploration due to coexisting thyroid nodule(s).
  • Of these, 33% (n = 3) had underlying thyroid malignancy (all papillary thyroid cancer) requiring thyroidectomy in addition to parathyroidectomy.
  • All but one patient had parathyroid adenoma as the cause of pHPT.
  • CONCLUSION: The routine use of preoperative thyroid US in patients with pHPT undergoing parathyroid surgery may aid in the timely diagnosis and treatment of coexisting thyroid disease.
  • [MeSH-major] Hyperparathyroidism / surgery. Parathyroidectomy. Preoperative Care / methods. Thyroid Gland / ultrasonography
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Carcinoma, Papillary / complications. Carcinoma, Papillary / pathology. Carcinoma, Papillary / ultrasonography. Female. Humans. Male. Middle Aged. Prevalence. Prospective Studies. Thyroid Diseases / complications. Thyroid Diseases / pathology. Thyroid Diseases / ultrasonography. Thyroid Neoplasms / complications. Thyroid Neoplasms / pathology. Thyroid Neoplasms / ultrasonography. Thyroid Nodule / complications. Thyroid Nodule / pathology. Thyroid Nodule / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19482296.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


39. Rubello D, Giannini S, Martini C, Piotto A, Rampin L, Fanti S, Armigliato M, Nardi A, Carpi A, Mariani G, Gross MD, Pelizzo MR: Minimally invasive radio-guided parathyroidectomy. Biomed Pharmacother; 2006 Apr;60(3):134-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the basis of preoperative imaging including Sestamibi scintigraphy and neck ultrasound (US), 263 patients (74% of the whole series) with evidence of a solitary parathyroid adenoma (PA) and a normal thyroid gland were addressed to MIRP and in 253 (96%) of them this minimally invasive neck exploration was successfully performed.
  • The most frequent cause of exclusion from MIRP in our series was the presence of concomitant Sestamibi avid thyroid nodules (68.5% of cases) that can give false positive results at radio-guided surgery.
  • In conclusion, MIRP is an effective treatment in patients with a high likelihood of a solitary PA and a normal thyroid gland at scintigraphy and US so that an accurate preoperative localizing imaging is required for MIRP.
  • Patients with concomitant Sestamibi avid thyroid nodules should be excluded from MIRP.
  • [MeSH-major] Adenoma / surgery. Gamma Cameras. Hyperparathyroidism, Primary / surgery. Minimally Invasive Surgical Procedures. Parathyroid Neoplasms / surgery. Parathyroidectomy. Radiology, Interventional / instrumentation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16524690.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


40. Romanchishen AF, Matveeva ZS: [A combination of diseases of the thyroid and asymptomatic adenoma of the parathyroid glands]. Vestn Khir Im I I Grek; 2006;165(1):40-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A combination of diseases of the thyroid and asymptomatic adenoma of the parathyroid glands].
  • The authors have analyzed the cases of diagnosis of asymptomatic tumors of the parathyroid gland made during 8814 operations on the thyroid in the period from 1995 through 2004.
  • A precision technique of operating allows the parathyroid tumors to be detected at the preclinical stage in all patients apart from a removal of the necessary volume of the thyroid tissue, guaranteed preservation of the laryngeal nerves and parathyroid glands.
  • [MeSH-major] Adenoma / complications. Parathyroid Neoplasms / complications. Thyroid Diseases / complications
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16568854.001).
  • [ISSN] 0042-4625
  • [Journal-full-title] Vestnik khirurgii imeni I. I. Grekova
  • [ISO-abbreviation] Vestn. Khir. Im. I. I. Grek.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


41. Aiad H, Abdou A, Bashandy M, Said A, Ezz-Elarab S, Zahran A: Computerized nuclear morphometry in the diagnosis of thyroid lesions with predominant follicular pattern. Ecancermedicalscience; 2009;3:146
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computerized nuclear morphometry in the diagnosis of thyroid lesions with predominant follicular pattern.
  • BACKGROUND: Differential diagnosis of thyroid lesions with predominantly follicular pattern is one of the most common problems in thyroid pathology.
  • Development of more objective and reproducible tools for diagnosis is needed.
  • This work is aimed at studying the role of nuclear morphometry in differential diagnosis of different thyroid lesions having predominant follicular pattern.
  • MATERIAL AND METHODS: Semiautomatic image analysis system was used to measure a total of 8 nuclear parameters in 48 thyroid lesions including seven nodular goiter (NG), 14 follicular adenoma (FA), 14 follicular carcinoma (FC) and 13 follicular variant papillary carcinoma (FVPC).
  • CONCLUSION: Nuclear morphometric parameters may help in the differentiation between neoplastic and non-neoplastic thyroid lesions and between FVPC and follicular neoplasms (FC and FA) but they have no value in the differentiation between FC and FA.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22276011.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3224013
  • [Keywords] NOTNLM ; Thyroid / differential diagnosis / nuclear morphometry
  •  go-up   go-down


42. Haghpanah V, Shooshtarizadeh P, Heshmat R, Larijani B, Tavangar SM: Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma. Appl Immunohistochem Mol Morphol; 2006 Dec;14(4):422-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma.
  • This retrospective study of thyroid histologic samples aimed to assess the clinical usefulness of survivin immunostaining for discrimination between follicular adenoma and carcinoma of thyroid.
  • Immunohistochemical staining for survivin was performed on 41 lesions from patients who had undergone surgery for either follicular adenoma or carcinoma of thyroid.
  • Survivin expression was significantly (P < 0.005) higher in the cases that received a diagnosis of carcinoma in comparison with follicular adenomas cases.
  • Odds ratio of follicular carcinoma for survivin expression was 21.375 (95% CI: 3.283 to 139.177).
  • Our results showed potential value of survivin in discrimination between follicular thyroid adenoma and follicular thyroid carcinoma.
  • We conclude that survivin is a potential candidate for further investigation in the proper histologic diagnosis of thyroid cancers.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122639.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


43. Mun HC, Brennan SC, Delbridge L, Wilkinson M, Brown EM, Conigrave AD: Adenomatous human parathyroid cells exhibit impaired sensitivity to L-amino acids. J Clin Endocrinol Metab; 2009 Sep;94(9):3567-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Primary hyperparathyroidism, which occurs most commonly in patients with adenomatous disease of a single parathyroid gland, arises as a result of impaired extracellular Ca(2+) (Ca(2+)(o))-dependent feedback on PTH secretion, a process mediated by the calcium-sensing receptor (CaR).
  • SETTING AND PATIENTS: Excess normal parathyroid tissue was obtained from parathyroid autotransplants at the time of thyroid surgery.
  • Samples of adenomatous tissue were obtained from histologically confirmed parathyroid adenomas.
  • RESULTS: Parathyroid adenomas exhibited reduced sensitivity to the CaR-active amino acid L-Phe, which affected both Ca(2+)(o)-dependent PTH secretion and Ca(2+)(o)-dependent intracellular Ca(2+) mobilization as a measure of CaR-dependent signaling in parathyroid cells.
  • [MeSH-major] Adenoma / secretion. Amino Acids / pharmacology. Parathyroid Neoplasms / secretion

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 May 24;277(21):18908-13 [11880385.001]
  • [Cites] Physiol Rev. 2001 Jan;81(1):239-297 [11152759.001]
  • [Cites] Eur J Clin Nutr. 2002 Nov;56(11):1072-80 [12428172.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38151-9 [15234970.001]
  • [Cites] J Clin Endocrinol Metab. 1978 Feb;46(2):267-75 [750604.001]
  • [Cites] Am J Physiol. 1989 Dec;257(6 Pt 1):G982-9 [2610264.001]
  • [Cites] J Endocrinol. 1996 Apr;149(1):135-44 [8676046.001]
  • [Cites] Surgery. 1998 Dec;124(6):1094-8; discussion 1098-9 [9854589.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):51739-44 [15579475.001]
  • [Cites] Surgery. 2005 Dec;138(6):1111-20; discussion 1120 [16360398.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Nov;291(5):G753-61 [17030896.001]
  • [Cites] Trends Endocrinol Metab. 2006 Dec;17(10):398-407 [17085057.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4814-9 [10781086.001]
  • [Cites] Endocrinology. 2000 Nov;141(11):4156-63 [11089548.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4789-94 [11134144.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33736-41 [12114500.001]
  • (PMID = 19567535.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Parathyroid Hormone; 0 / Receptors, Calcium-Sensing; 47E5O17Y3R / Phenylalanine; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2741716
  •  go-up   go-down


44. Alaedeen DI, Khiyami A, McHenry CR: Fine-needle aspiration biopsy specimen with a predominance of Hürthle cells: a dilemma in the management of nodular thyroid disease. Surgery; 2005 Oct;138(4):650-6; discussion 656-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy specimen with a predominance of Hürthle cells: a dilemma in the management of nodular thyroid disease.
  • BACKGROUND: A fine-needle aspiration biopsy (FNAB) specimen of a thyroid nodule with a predominance of Hürthle cells usually is indicative of a Hürthle cell neoplasm, but it also may occur with nonneoplastic disease.
  • METHODS: A prospective nodular thyroid disease database was used to identify patients with a FNAB specimen consisting of a predominance of Hürthle cells.
  • RESULTS: Of the 738 patients with nodular thyroid disease, 622 had a FNAB specimen.
  • The FNAB specimen was interpreted as consistent with a Hürthle cell neoplasm in 45 (7%) patients, 7 (16%) with carcinoma, 21 (47%) with adenoma, 12 (27%) with adenomatous hyperplasia, and 5 (11%) with thyroiditis.
  • No significant differences in age (x +/- SD) (51 +/- 17 vs 54 +/- 17 y), sex (female/male ratio, 6/1 vs 15/2), nodule size (3.9 +/- 1.9 vs 3.4 +/- 2.0 cm), weight of excised thyroid tissue (42 +/- 27 vs 33 +/- 30 g), or functional status of the thyroid gland was observed between patients with neoplastic (n = 28, 62%) versus nonneoplastic (n = 17, 38%) disease.
  • CONCLUSIONS: Neoplastic disease accounts for two thirds of the pathology in patients with a predominance of Hürthle cells on FNAB specimen and neither clinical nor cytologic features reliably exclude Hürthle cell adenoma or carcinoma.
  • As a result, thyroidectomy is recommended for all patients with a thyroid nodule and a predominance of Hürthle cells on FNAB specimen.
  • [MeSH-major] Biopsy, Fine-Needle. Oxyphil Cells / pathology. Thyroid Gland / pathology. Thyroid Nodule / pathology
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Adult. Aged. Carcinoma / pathology. Databases, Factual. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Single-Blind Method. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269293.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Matsuo SE, Fiore AP, Siguematu SM, Ebina KN, Friguglietti CU, Ferro MC, Kulcsar MA, Kimura ET: Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues. Arq Bras Endocrinol Metabol; 2010 Jun;54(4):406-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues.
  • OBJECTIVE: To investigate the expression of SMAD proteins in human thyroid tissues since the inactivation of TGF-beta/activin signaling components is reported in several types of cancer.
  • Although TGF-beta and activin exert antiproliferative roles in thyroid follicular cells, thyroid tumors express high levels of these proteins.
  • MATERIALS AND METHODS: The protein expression of SMADs was evaluated in multinodular goiter, follicular adenoma, papillary and follicular carcinomas by immunohistochemistry.
  • RESULTS: The expression of pSMAD2/3, SMAD4 and SMAD7 was observed in both benign and malignant thyroid tumors.
  • Although pSMAD2/3, SMAD4 and SMAD7 exhibited high cytoplasmic staining in carcinomas, the nuclear staining of pSMAD2/3 was not different between benign and malignant lesions.
  • CONCLUSIONS: The finding of SMADs expression in thyroid cells and the presence of pSMAD2/3 and SMAD4 proteins in the nucleus of tumor cells indicates propagation of TGF-beta/activin signaling.
  • However, the high expression of the inhibitory SMAD7, mostly in malignant tumors, could contribute to the attenuation of the SMADs antiproliferative signaling in thyroid carcinomas.
  • [MeSH-major] Activins / physiology. Smad Proteins, Receptor-Regulated / metabolism. Thyroid Neoplasms / metabolism. Transforming Growth Factor beta / physiology
  • [MeSH-minor] Adenoma / metabolism. Carcinoma, Papillary, Follicular / metabolism. Goiter, Nodular / metabolism. Humans. Signal Transduction / physiology. Smad2 Protein / analysis. Smad3 Protein / analysis. Smad4 Protein / analysis. Smad7 Protein / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625653.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / SMAD2 protein, human; 0 / SMAD3 protein, human; 0 / SMAD4 protein, human; 0 / SMAD7 protein, human; 0 / Smad Proteins, Receptor-Regulated; 0 / Smad2 Protein; 0 / Smad3 Protein; 0 / Smad4 Protein; 0 / Smad7 Protein; 0 / Transforming Growth Factor beta; 104625-48-1 / Activins
  •  go-up   go-down


46. Pujani M, Arora B, Pujani M, Singh SK, Tejwani N: Role of Ki-67 as a proliferative marker in lesions of thyroid. Indian J Cancer; 2010 Jul-Sep;47(3):304-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of Ki-67 as a proliferative marker in lesions of thyroid.
  • BACKGROUND: Specific criteria are used to diagnose thyroid neoplasms; however, the distinction between certain neoplasms, such as follicular adenoma and carcinoma, could be difficult.
  • AIMS: To evaluate the role of the proliferative marker Ki-67 in nonneoplastic and neoplastic lesions of the thyroid, with a special emphasis on the distinction between follicular adenoma and follicular carcinoma.
  • MATERIALS AND METHODS: One hundred cases of thyroid lesions, including 50 nonneoplastic and 50 neoplastic lesions, were retrieved from the archives of the Department of Pathology, Pt.
  • RESULTS: Ki-67 labeling index (LI) showed a progressive rise from multinodular goiter to benign to malignant neoplasms.
  • A statistically significant difference was observed in Ki-67 counts between multinodular goiter vs papillary carcinoma (P < 0.05) and follicular adenoma vs follicular carcinoma (P < 0.05).
  • CONCLUSIONS: In the present study, Ki-67 was found to be useful in differentiating between follicular adenoma and follicular carcinoma, but since the sample size of our study was small, larger studies are needed to confirm this observation as well as to assign a cutoff value for differentiating benign from malignant tumors.
  • [MeSH-major] Adenoma / diagnosis. Biomarkers, Tumor / metabolism. Carcinoma / diagnosis. Goiter, Nodular / diagnosis. Ki-67 Antigen / metabolism. Thyroid Gland / metabolism. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Diagnosis, Differential. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Cancer. 2011 Jul-Sep;48(3):378 [21921351.001]
  • (PMID = 20587907.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


47. Lappinga PJ, Kip NS, Jin L, Lloyd RV, Henry MR, Zhang J, Nassar A: HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules. Cancer Cytopathol; 2010 Oct 25;118(5):287-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules.
  • BACKGROUND: Up to 80% of thyroid nodules with an indeterminate diagnosis on fine-needle aspiration (FNA) (eg, "suspicious for follicular neoplasm") prove to be benign at the time of surgical resection.
  • Ancillary tests in current use are limited in their ability to improve the preoperative detection of malignant follicular thyroid nodules.
  • Studies using paraffin-embedded tissue have indicated that high mobility group AT-hook 2 (HMGA2) overexpression is present in a high percentage of malignant thyroid neoplasms but not in benign thyroid neoplasms.
  • In the current study, the ability of HMGA2 overexpression analysis to preoperatively distinguish benign from malignant thyroid nodules by reverse transcriptase-polymerase chain reaction (RT-PCR) on suspicious cytologic smears was evaluated.
  • METHODS: Patients who underwent thyroid FNA and subsequent thyroid resection from 2001 through 2007 were identified.
  • A subset of these patients who had a cytologic diagnosis of "suspicious" underwent HMGA2 expression analysis.
  • With an HMGA2 overexpression change of 5.9-fold or greater compared with a thyroid tumor cell line as a positive cutoff, the test was found to have the following overall performance for detecting malignant nodules: sensitivity of 71%, specificity of 97%, positive predictive value of 94%, and negative predictive value of 84%.
  • HMGA2 overexpression was found to have low sensitivity for detecting Hurthle cell carcinoma (33%).
  • CONCLUSIONS: HMGA2 mRNA expression analysis can be performed on cytologic smears and demonstrates a high specificity and positive predictive value and relatively high sensitivity and negative predictive value for detecting malignancy in "suspicious" thyroid aspirate specimens.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. HMGA2 Protein / genetics. Thyroid Gland / metabolism. Thyroid Nodule / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / genetics. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Child. Cytodiagnosis / methods. Diagnosis, Differential. Female. Goiter / diagnosis. Goiter / genetics. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • (PMID = 20597139.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGA2 Protein; 0 / RNA, Messenger
  •  go-up   go-down


48. Tzelepi VN, Tsamandas AC, Vlotinou HD, Vagianos CE, Scopa CD: Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. Mod Pathol; 2008 Jan;21(1):22-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms.
  • Their role in thyroid carcinogenesis has not yet been elucidated.
  • This study investigates the expression of occludin and claudin-1, -4 and -7 in thyroid neoplasms.
  • Ninety-one thyroid neoplasms (15 follicular adenomas, 15 follicular carcinomas, 26 papillary carcinomas, 16 papillary microcarcinomas, 8 medullary carcinomas, 3 poorly differentiated carcinomas, 8 undifferentiated carcinomas) were immunostained with antibodies against occludin and claudin-1, -4 and -7.
  • Thirteen out of 15 follicular adenomas, 10/15 follicular carcinomas, 24/26 papillary carcinomas, 15/16 papillary microcarcinomas, 1/8 medullary carcinomas, 2/3 poorly differentiated carcinomas and 2/8 undifferentiated carcinomas exhibited claudin-1 expression, whereas claudin-4 was expressed in 13/15, 12/15, 23/26, 13/16, 7/8, 2/3 and 2/8 of the tumors, respectively, and claudin-7 expression was found in 67, 33, 73, 69, 25, 0 and 13% of the cases, respectively.
  • Occludin was expressed in 100% follicular adenomas, 80% follicular carcinomas, 96% papillary carcinomas, 50% papillary microcarcinomas, 50% medullary carcinomas, 33% poorly differentiated carcinomas and 88% undifferentiated carcinomas.
  • Claudin-1 was additionally reduced in medullary carcinomas and claudin-7 in follicular, medullary and poorly differentiated carcinomas.
  • Dedifferentiation of the thyroid carcinomas is accompanied by reduction in claudin-1, -4 and -7 expression.
  • A differential expression of tight junction proteins in the different histologic types of thyroid gland is noted.
  • Additionally, claudin-1 expression may be an important prognostic indicator of recurrence in thyroid carcinomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Membrane Proteins / analysis. Thyroid Neoplasms / chemistry. Tight Junctions / chemistry
  • [MeSH-minor] Adenoma / chemistry. Adult. Aged. Aged, 80 and over. Carcinoma, Medullary / chemistry. Carcinoma, Papillary / chemistry. Cell Differentiation. Claudin-1. Claudin-4. Claudins. Disease-Free Survival. Down-Regulation. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Occludin. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962811.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / CLDN4 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Claudins; 0 / Membrane Proteins; 0 / OCLN protein, human; 0 / Occludin
  •  go-up   go-down


49. Deiana L, Lai ML, Carta G, Mariotti S: Correspondence between ultrasonography and histological features in a single thyroid nodule with coexisting follicular adenoma and papillary carcinoma. Thyroid; 2008 Jul;18(7):813-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correspondence between ultrasonography and histological features in a single thyroid nodule with coexisting follicular adenoma and papillary carcinoma.
  • [MeSH-major] Adenoma / pathology. Adenoma / ultrasonography. Carcinoma, Papillary / pathology. Carcinoma, Papillary / ultrasonography. Thyroid Neoplasms / ultrasonography. Thyroid Nodule / pathology. Thyroid Nodule / ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18631017.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


50. Yoshizawa K, Jelezcova E, Brown AR, Foley JF, Nyska A, Cui X, Hofseth LJ, Maronpot RM, Wilson SH, Sepulveda AR, Sobol RW: Gastrointestinal hyperplasia with altered expression of DNA polymerase beta. PLoS One; 2009 Aug 05;4(8):e6493
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These mice present with an elevated incidence of spontaneous histologic lesions, including cataracts, hyperplasia of Brunner's gland and mucosal hyperplasia in the duodenum.
  • We observed elevated expression of Pol beta in stomach adenomas and thyroid follicular carcinomas, but reduced Pol beta expression in esophageal adenocarcinomas and squamous carcinomas.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2007 Jan;21(1):26-34 [17116746.001]
  • [Cites] Int J Cancer. 2007 Apr 15;120(8):1748-54 [17230526.001]
  • [Cites] DNA Repair (Amst). 2007 Jun 1;6(6):695-711 [17337257.001]
  • [Cites] Nucleic Acids Res. 2007;35(8):2596-608 [17426133.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1356-63 [17166880.001]
  • [Cites] Stem Cells. 2007 Dec;25(12):3085-92 [17823235.001]
  • [Cites] Mol Cell. 2008 Feb 29;29(4):413-5 [18313379.001]
  • [Cites] Mol Cell. 2008 Feb 29;29(4):477-87 [18313385.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jun 27;371(2):225-9 [18433721.001]
  • [Cites] Mol Pharmacol. 2008 Aug;74(2):505-16 [18477668.001]
  • [Cites] Chin Med Sci J. 2008 Jun;23(2):108-12 [18686630.001]
  • [Cites] Cancer Lett. 2008 Nov 28;271(2):272-80 [18662849.001]
  • [Cites] Biol Reprod. 2008 Nov;79(5):824-31 [18650495.001]
  • [Cites] Gene. 2009 Jan 1;428(1-2):20-4 [18976699.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):740-6 [19147782.001]
  • [Cites] Carcinogenesis. 2009 May;30(5):763-8 [19237606.001]
  • [Cites] Cancer Res. 2009 Jun 15;69(12):5177-85 [19491276.001]
  • [Cites] J Biol Chem. 2004 Oct 15;279(42):43952-60 [15297456.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9470-7 [15485914.001]
  • [Cites] Cell Cycle. 2004 Aug;3(8):998-1001 [15280658.001]
  • [Cites] J Natl Cancer Inst. 1969 Dec;43(6):1353-64 [5396221.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):1938-43 [1149018.001]
  • [Cites] Lab Anim Sci. 1983 Jun;33(3):273-86 [6876733.001]
  • [Cites] Cancer Lett. 1984 Nov;25(1):19-23 [6518449.001]
  • [Cites] J Comp Pathol. 1986 Jan;96(1):89-94 [3455952.001]
  • [Cites] Lab Anim. 1989 Oct;23(4):324-7 [2811271.001]
  • [Cites] Exp Pathol. 1990;38(2):129-34 [2344869.001]
  • [Cites] Cancer Res. 1992 Sep 1;52(17):4824-7 [1511447.001]
  • [Cites] Science. 1994 Jul 1;265(5168):103-6 [8016642.001]
  • [Cites] Lab Anim Sci. 1994 Oct;44(5):531-3 [7844967.001]
  • [Cites] Cancer Lett. 1995 May 8;91(2):177-83 [7767907.001]
  • [Cites] Nature. 1996 Jan 11;379(6561):183-6 [8538772.001]
  • [Cites] Lab Invest. 1996 Feb;74(2):513-8 [8780168.001]
  • [Cites] J Exp Zool. 1997 Feb 15;277(3):245-54 [9062998.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10324-9 [9294209.001]
  • [Cites] Vet Pathol. 1997 Nov;34(6):605-14 [9396142.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9997-10002 [9707589.001]
  • [Cites] Carcinogenesis. 1999 Jun;20(6):1049-54 [10357787.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1825-30 [10469630.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7673-7 [15520167.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8526-33 [15574758.001]
  • [Cites] Nucleic Acids Res. 2005;33(1):280-8 [15647510.001]
  • [Cites] J Invest Surg. 2004 Nov-Dec;17(6):327-31 [15764500.001]
  • [Cites] DNA Repair (Amst). 2005 May 2;4(5):583-93 [15811630.001]
  • [Cites] EMBO J. 2005 Jul 6;24(13):2447-57 [15933716.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6113-7 [10626800.001]
  • [Cites] EMBO J. 2000 Mar 15;19(6):1397-404 [10716939.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):807-10 [10866204.001]
  • [Cites] Leuk Res. 2000 Aug;24(8):705-18 [10936423.001]
  • [Cites] Carcinogenesis. 2000 Sep;21(9):1691-700 [10964101.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(1):298-309 [11113204.001]
  • [Cites] Science. 2001 Feb 16;291(5507):1284-9 [11181991.001]
  • [Cites] Langenbecks Arch Surg. 2001 Apr;386(3):163-71 [11382316.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6181-7 [11593426.001]
  • [Cites] J Mol Biol. 2002 Feb 1;315(5):1039-47 [11827474.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1524-30 [11888930.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6860-5 [11983862.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3511-4 [12067997.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6061-4 [12414629.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1213-22 [12453427.001]
  • [Cites] DNA Repair (Amst). 2002 Apr 29;1(4):317-33 [12509250.001]
  • [Cites] Curr Gastroenterol Rep. 2003 Apr;5(2):171-5 [12631460.001]
  • [Cites] DNA Repair (Amst). 2003 May 13;2(5):609-22 [12713817.001]
  • [Cites] Pathologe. 2003 May;24(3):196-203 [12739053.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5799-807 [14522902.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39951-9 [12882965.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1887-94 [14679184.001]
  • [Cites] FEBS Lett. 2004 May 21;566(1-3):147-50 [15147885.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3830-7 [15172990.001]
  • [Cites] Mol Cancer Ther. 2004 Aug;3(8):955-67 [15299078.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):223-31 [15368105.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6394-400 [16024643.001]
  • [Cites] Cell. 2005 Sep 23;122(6):957-68 [16169070.001]
  • [Cites] Mutagenesis. 2006 Jan;21(1):55-9 [16399847.001]
  • [Cites] Mol Cell. 2006 Apr 7;22(1):51-62 [16600869.001]
  • [Cites] Dis Esophagus. 2006;19(3):172-6 [16722994.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):523-5 [16739313.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7460-5 [16885342.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5104-11 [16951227.001]
  • [Cites] Cell. 2006 Nov 17;127(4):709-20 [17110331.001]
  • (PMID = 19654874.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / 1 R01 AG24364-01; United States / NIEHS NIH HHS / ES / Z01 ES050158; United States / NIEHS NIH HHS / ES / Z01 ES050159; United States / NIA NIH HHS / AG / R01 AG024364; United States / NCI NIH HHS / CA / 1P50 CA 097190 01A1; United States / NCI NIH HHS / CA / 1 P20 CA132385-01; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / P20 CA132385; United States / NCI NIH HHS / CA / P50 CA097190; United States / NCI NIH HHS / CA / P20 CA103730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.- / DNA Polymerase beta
  • [Other-IDs] NLM/ PMC2716528
  •  go-up   go-down


51. Tate G, Suzuki T, Endo Y, Mitsuya T: A novel mutation of the PTEN gene in a Japanese patient with Cowden syndrome and bilateral breast cancer. Cancer Genet Cytogenet; 2008 Jul;184(1):67-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cowden syndrome (CS), also known as multiple hamartoma syndrome, is an autosomal dominant cancer syndrome associated with a high risk of breast and thyroid cancers.
  • The phosphatase and tensin homolog gene (PTEN) encodes a lipid phosphatase that contains a PTPase domain and a C2 domain and plays a role as a tumor suppressor that negatively regulates the cell-survival signaling pathway initiated by phosphatidylinositol 3-kinase (PI3K).
  • In one patient, who suffered from bilateral breast cancer, thyroid adenoma, and gastric malignant lymphoma, we found a single-base substitution in exon 2 (115G>C) of the PTEN gene.
  • [MeSH-minor] Adenoma / complications. Adenoma / genetics. Base Sequence. DNA Primers. Female. Humans. Polymerase Chain Reaction. Thyroid Neoplasms / complications. Thyroid Neoplasms / genetics


52. Choi H, Kim S, Moon JH, Lee YH, Rhee Y, Kang ES, Ahn CW, Cha BS, Lee EJ, Kim KR, Lee HC, Jeong SY, Kim HJ, Lim SK: Multiple endocrine neoplasia type 1 with multiple leiomyomas linked to a novel mutation in the MEN1 gene. Yonsei Med J; 2008 Aug 30;49(4):655-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MEN1 is characterized by the presence of functioning and nonfunctioning tumors or hyperplasia of the pituitary gland, parathyroid glands, and pancreatic islet cells.
  • In addition, MEN1 carriers can have adrenal or thyroid tumors and non-endocrine tumors, such as lipomas, angiofibromas, and leiomyomas.
  • Endoscopic ultrasonography demonstrated esophageal leiomyoma and pancreatic islet cell tumor.
  • This is the first case of MEN1 accompanied with multiple leiomyomas, parathyroid adenoma, pituitary adenoma, pancreatic tumor, and adrenal tumor.


53. Garg M, Kanojia D, Suri S, Gupta S, Gupta A, Suri A: Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer. J Clin Endocrinol Metab; 2009 Nov;94(11):4613-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer.
  • CONTEXT: Cancer-testis antigens are the unique class of testis proteins expressed in tumor but not healthy tissue except testis and might represent ideal targets for the development of novel diagnostics and therapeutic methods in thyroid cancer, which is the most common malignancy of the endocrine system.
  • OBJECTIVE: Our objective was to investigate the clinical relevance of cancer-testis antigen sperm-associated antigen 9 (SPAG9) as early diagnostic and therapeutic target in thyroid cancer.
  • DESIGN, SETTING, AND SUBJECTS: SPAG9 gene and protein expression was determined in thyroid cancer cell lines in 138 thyroid tumor specimens, 60 adjacent noncancerous tissues (ANCT), 22 multinodular goiters (nonneoplastic hyperplasia), and 20 follicular adenoma tissue samples by RT-PCR, in situ RNA hybridization, and immunohistochemistry.
  • Humoral immune response against SPAG9 in thyroid cancer patients was analyzed using ELISA.
  • RESULTS: SPAG9 mRNA and protein expression was detected in 78% of the thyroid cancer patients but not multiple goiters and follicular adenoma disease patients.
  • It is interesting to note that majority of early-stage (T1) thyroid cancer patients exhibited higher antibody response against SPAG9.
  • Small interfering RNA-mediated knockdown of SPAG9 expression in thyroid cancer cell significantly reduced cellular growth and colony formation.
  • CONCLUSIONS: SPAG9 expression may play a role in cellular growth and thyroid carcinogenesis.
  • These findings support a potential role for SPAG9 as diagnostic biomarker as well as a possible therapeutic target in thyroid cancer treatment.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Biomarkers, Tumor / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Cell Division. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Gene Expression Regulation, Neoplastic. Goiter / blood. Humans. Immunohistochemistry. Neoplasm Staging. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820019.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / SPAG9 protein, human
  •  go-up   go-down


54. Cho Mar K, Eimoto T, Tateyama H, Arai Y, Fujiyoshi Y, Hamaguchi M: Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology; 2006 Feb;48(3):286-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions.
  • AIMS: To examine expression of matrix metalloproteinases (MMPs) and related proteins in follicular thyroid lesions (FTLs) and to determine their usefulness for differential diagnosis of FTLs, particularly between minimally invasive carcinoma and adenoma.
  • METHODS AND RESULTS: Six widely invasive follicular carcinomas (WIFCs), 15 minimally invasive follicular carcinomas (MIFCs), 19 follicular adenomas (FAs) and 10 adenomatous goitres (AGs) were analysed immunohistochemically for MMP-1, MMP-2, MMP-7, MMP-9, membrane-type 1-MMP (MT1-MMP) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2).
  • [MeSH-major] Adenocarcinoma, Follicular / chemistry. Adenoma / chemistry. Matrix Metalloproteinases / analysis. Thyroid Neoplasms / chemistry
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Matrix Metalloproteinase 2 / analysis. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 7 / analysis. Matrix Metalloproteinase 7 / genetics. Middle Aged. Neoplasm Invasiveness. RNA, Messenger / analysis. Thyroid Gland / chemistry. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430475.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


55. Ingui CJ, Shah NP, Oates ME: Endocrine neoplasm scintigraphy: added value of fusing SPECT/CT images compared with traditional side-by-side analysis. Clin Nucl Med; 2006 Nov;31(11):665-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These cases included: 4 I-131 (posttherapy thyroid cancer), 2 I-123 (pretherapy thyroid cancer), 2 In-111 OctreoScan (neuroendocrine neoplasm), one Tc-99m sestamibi (thyroid cancer), one Tc-99m tetrofosmin (parathyroid adenoma), and one I-123 MIBG (adrenergic neoplasm).
  • [MeSH-major] Endocrine Gland Neoplasms / diagnosis. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Subtraction Technique. Tomography, Emission-Computed, Single-Photon / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17053381.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Zheng YX, Xu SM, Wang P, Chen L: Preoperative localization and minimally invasive management of primary hyperparathyroidism concomitant with thyroid disease. J Zhejiang Univ Sci B; 2007 Sep;8(9):626-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative localization and minimally invasive management of primary hyperparathyroidism concomitant with thyroid disease.
  • The coexistence of thyroid diseases with primary hyperparathyroidism (PHPT) can present a challenge in the clinical diagnosis and management for these patients.
  • This study aims to determine the frequency of coexisting thyroid gland lesions in a consecutive series patients with PHPT, and to analyze the clinical features, diagnosis and treatment of these patients.
  • Twenty-two cases of a total of 52 PHPT patients who had synchronous thyroid and parathyroid pathology were surgically managed in this study.
  • Thirteen patients had ipsilateral thyroid nodules, and 9 patients had thyroid nodules in contralateral or bilateral side.
  • Seventeen nodular goiter (32.7%), 2 thyroiditis (3.8%), 2 thyroid adenoma (3.8%) and 1 thyroid carcinoma (1.9%) coexisting with parathyroid adenoma were pathologically diagnosed.
  • A high incidence of thyroid diseases that coexisted with PHPT in literatures was briefly reviewed.
  • Our study illustrated the need for clinical awareness of concomitant PHPT and thyroid disease.
  • A combination of US, computed tomography (CT) and MIBI scintigraphy would be recommended for preoperative localization of enlarged parathyroid adenoma and for evaluation of thyroid lesions.
  • Synchronous treatment of associated thyroid abnormalities is desirable, and open minimally invasive surgical approach with additional resection of isolated ipsilateral thyroid nodules is possible in some of these patients.
  • [MeSH-major] Hyperparathyroidism, Primary / epidemiology. Hyperparathyroidism, Primary / surgery. Minimally Invasive Surgical Procedures / statistics & numerical data. Parathyroidectomy / statistics & numerical data. Thyroid Nodule / epidemiology. Thyroid Nodule / surgery. Thyroidectomy / statistics & numerical data

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Clin Endocrinol Diabetes. 1999;107(7):457-61 [10595598.001]
  • [Cites] Aust N Z J Surg. 2000 Apr;70(4):285-7 [10779061.001]
  • [Cites] Endocrinol Metab Clin North Am. 2000 Sep;29(3):479-502 [11033757.001]
  • [Cites] Surgery. 2001 Jun;129(6):720-9 [11391371.001]
  • [Cites] Chin Med J (Engl). 2002 Jun;115(6):939-41 [12136811.001]
  • [Cites] Thyroid. 2002 Dec;12(12):1109-12 [12593724.001]
  • [Cites] J Am Coll Surg. 2003 Apr;196(4):541-8 [12691928.001]
  • [Cites] Zentralbl Chir. 2003 Jul;128(7):561-5 [12884142.001]
  • [Cites] An Otorrinolaringol Ibero Am. 2003;30(5):459-66 [14648926.001]
  • [Cites] Surgery. 1982 Sep;92(3):454-8 [6896772.001]
  • [Cites] Surg Gynecol Obstet. 1985 May;160(5):407-8 [3992443.001]
  • [Cites] Nucl Med Commun. 1989 Nov;10(11):791-4 [2532313.001]
  • [Cites] Ann Surg. 1992 Apr;215(4):300-17 [1558410.001]
  • [Cites] Acta Chir Belg. 2004 Oct;104(5):568-71 [15571025.001]
  • [Cites] Surg Today. 2005;35(5):351-6 [15864415.001]
  • [Cites] World J Surg. 2005 Sep;29(9):1180-4 [16091985.001]
  • [Cites] Endokrynol Pol. 2006;57 Suppl A:71-4 [17091460.001]
  • (PMID = 17726743.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Number-of-references] 19
  • [Other-IDs] NLM/ PMC1963428
  •  go-up   go-down


57. Cecchin D, Lumachi F, Marino F, Stramare R, Basso U, Grassetto G, Bui F: Thyroid C-cell hyperplasia shown by combined In-111 pentetreotide, Tc-99m pertechnetate, and Tc-99m MIBI scintigraphy. Clin Nucl Med; 2007 May;32(5):378-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid C-cell hyperplasia shown by combined In-111 pentetreotide, Tc-99m pertechnetate, and Tc-99m MIBI scintigraphy.
  • [MeSH-major] Indium Radioisotopes / therapeutic use. Sodium Pertechnetate Tc 99m / pharmacology. Somatostatin / analogs & derivatives. Technetium Tc 99m Sestamibi / pharmacology. Thyroid Gland / pathology. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adenoma / pathology. Cell Proliferation. Colorectal Neoplasms / pathology. Diagnosis, Differential. Humans. Hyperplasia. Male. Middle Aged. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology. Thyroid Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452867.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indium Radioisotopes; 51110-01-1 / Somatostatin; 971Z4W1S09 / Technetium Tc 99m Sestamibi; A0730CX801 / Sodium Pertechnetate Tc 99m; G083B71P98 / pentetreotide
  •  go-up   go-down


58. Xu WC, Chen SR, Huang JX, Zheng ZC, Chen LX, Lin JJ, Li YG: Expression and distribution of S-100 protein, CD83 and apoptosis-related proteins (Fas, FasL and Bcl-2) in thyroid tissues of autoimmune thyroid diseases. Eur J Histochem; 2007 Oct-Dec;51(4):291-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and distribution of S-100 protein, CD83 and apoptosis-related proteins (Fas, FasL and Bcl-2) in thyroid tissues of autoimmune thyroid diseases.
  • Previous studies have shown that dendritic cells (DCs) and apoptosis-related proteins play a critical role in the pathogenesis of autoimmune thyroid diseases (ATD).
  • This study was designed to investigate the expression and distribution of S-100 protein, CD83 and apoptosis-related proteins (Fas, FasL and Bcl-2) in the thyroid tissues of ATD and their role in ATD pathogenesis as determined by immunochemical staing techniques and other methods.
  • Pathological tissues of 30 patients with Hashimoto's thyroiditis (HT), 30 patients with Graves' disease (GD) and 30 cases of thyroid follicular adenoma (TFA, as control) were used for this study.
  • HT thyrocytes adjacent to thyroid infiltrating lymphocytes (TILs) showed greater increases in the levels of Fas and FasL than did the GD thyrocytes while HT TILs exhibited lower expression of Fas and FasL than did the GD TILs.
  • Up-regulation of both the number and matured functions of DCs may lead to the presentation of more antigens to lymphocytes which are related to the development of autoimmune thyroid diseases.
  • [MeSH-major] Antigens, CD / metabolism. Apoptosis Regulatory Proteins / metabolism. Immunoglobulins / metabolism. Membrane Glycoproteins / metabolism. S100 Proteins / metabolism. Thyroid Gland / metabolism. Thyroiditis, Autoimmune / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, CD95 / metabolism. Fas Ligand Protein / metabolism. Female. Flow Cytometry. Fluorescent Antibody Technique, Indirect. Graves Disease / metabolism. Graves Disease / pathology. Humans. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Autoimmune Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162459.001).
  • [ISSN] 1121-760X
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD95; 0 / Apoptosis Regulatory Proteins; 0 / CD83 antigen; 0 / Fas Ligand Protein; 0 / Immunoglobulins; 0 / Membrane Glycoproteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / S100 Proteins
  •  go-up   go-down


59. Mai KT, Elmontaser G, Perkins DG, Thomas J, Stinson WA: Benign Hürthle cell adenoma with papillary architecture: a benign lesion mimicking oncocytic papillary carcinoma. Int J Surg Pathol; 2005 Jan;13(1):37-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign Hürthle cell adenoma with papillary architecture: a benign lesion mimicking oncocytic papillary carcinoma.
  • We studied the significance of encapsulated Hürthle cell thyroid nodules with papillary structures lacking the nuclear features of papillary thyroid carcinoma (PTC); 19 cases fulfilling these criteria were encountered The patients' ages ranged from 22 to 40 years (32+/-6), and the F:M ratio was 3:1 The tumors measured from 0.5-5 cm (2+/-1.1).
  • The diameter of the tumor cell nuclei ranged from 5.6 to 7.2 microns.
  • In view of (1) the encapsulation and the uniformity of the constituent cells, (2) the negative or weak immunoreactivity for galectin-3 and HBME and negative to moderate immunoreactivity for CK19, and (3) the absence or paucity of nuclear criteria for the diagnosis of PTC and the absence of lymph node metastasis in all study cases, we believe that these lesions represent the papillary variant of oncocytic follicular adenoma (Hürthle cell adenoma).
  • [MeSH-major] Adenoma / pathology. Adenoma, Oxyphilic / pathology. Carcinoma, Papillary, Follicular / diagnosis. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Chromatin / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735853.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromatin
  •  go-up   go-down


60. Brzac HT: [Ultrasonography-guided therapeutic procedures in the neck region]. Acta Med Croatica; 2009 Dec;63 Suppl 3:21-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PEIT is used in the treatment of parathyroid glands, especially secondary hyperparathyroidism, thyroid nodules (toxic adenoma, goiters and cysts), other cysts on the neck, and cervical metastases of thyroid cancer.
  • In this way, reduction or disappearance of the nodes can be achieved, along with functional normalization (for parathyroid glands and toxic adenoma), with longer or shorter disease remission or complete recovery.
  • The treatment gives best results in combination with vitamin D analogs, if 1-2 parathyroid glands are enlarged, and for residual parathyroid gland after parathyroidectomy.
  • Therapeutic effect is manifested in the size reduction or complete fibrozation of the gland, reduction or disappearance of vascularization, and a decrease in the parathormone level.
  • PEIT produced best results in cysts (thyroid cysts, parathyroid cysts or other cysts on the neck), and can replace surgery.
  • Therapy for toxic and autonomous thyroid adenoma and toxic nodular goiter by ethanol injection is accepted as one of the methods for treating patients that refuse radiation therapy or surgery.
  • The goals of the treatment are nodal size reduction, normalization of thyroid hormones and TSH, and an improved subjective condition of the patient.
  • PEIT is also recommended for the treatment of thyroid cancer neck metastases as an alternative procedure in patients at a high risk of reoperation, those that refuse surgery, and those with radioiodine-negative metastasis.
  • [MeSH-major] Ethanol / administration & dosage. Hyperparathyroidism, Secondary / therapy. Sclerotherapy. Thyroid Diseases / therapy. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20235370.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


61. Roberts SS, Mendonça-Torres MC, Jensen K, Francis GL, Vasko V: GABA receptor expression in benign and malignant thyroid tumors. Pathol Oncol Res; 2009 Dec;15(4):645-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GABA receptor expression in benign and malignant thyroid tumors.
  • The role of neurotransmitters and neurotrophic factors has not yet been examined in thyroid cancer.
  • To determine the possible involvement of neurotransmitter systems in thyroid carcinogenesis we characterized the patterns of gamma-aminobutyric acid (GABA) receptor expression in normal thyroid and thyroid tumors.
  • We examined the expression patterns of the GABAergic system in 70 human thyroid tumor samples (13 follicular adenomas, 14 follicular carcinomas, 43 papillary carcinomas) and adjacent normal thyroid by immunohistochemistry.
  • GABAergic system mRNA expression in thyroid cancer cell lines derived from primary (FTC133) and metastatic tumors (FTC236 and FTC238) was examined by real time PCR.
  • Overall, GABA receptor expression is increased in tumors compared to normal thyroid tissue.
  • Expression of GABAA receptor beta2 was detected in the vasculature of normal thyroid and thyroid tumors but not in thyroid cancer cells.
  • GABAA alpha2 was detected in metastatic-derived but not in primary-tumor derived cell lines.
  • Expression levels of GABAB R2 and GABA receptor associated protein (GABARAP) are increased in adenomas and thyroid cancer suggesting their role in early stages of thyroid tumorigenesis.
  • This study represents the first demonstration of GABA receptor expression in human thyroid tissue and suggests that the GABAergic system is involved in thyroid carcinogenesis.
  • [MeSH-major] Receptors, GABA / metabolism. Thyroid Gland / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / metabolism. Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenoma / metabolism. Adenoma / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Line, Tumor. Humans. Microtubule-Associated Proteins / metabolism. Receptors, GABA-A / metabolism. Receptors, GABA-B / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Comp Biochem Physiol A Mol Integr Physiol. 2006 Jul;144(3):332-44 [16527506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2803-8 [17296934.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Sep;19(3):383-90 [11144533.001]
  • [Cites] Psychoneuroendocrinology. 1987;12(1):53-9 [2884685.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):69-80 [18221027.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1981 Aug;317(1):61-6 [7279009.001]
  • [Cites] Endocr Dev. 2007;10:140-72 [17684395.001]
  • [Cites] Thyroid. 2000 Jul;10(7):587-94 [10958311.001]
  • [Cites] Cell Tissue Res. 1981;220(4):873-9 [7296659.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2270-82 [11948410.001]
  • [Cites] Life Sci. 1990;46(21):1489-501 [2162457.001]
  • [Cites] Annu Rev Neurosci. 1994;17:569-602 [7516126.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51841-50 [14530254.001]
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):27-30 [11121859.001]
  • [Cites] Prog Exp Tumor Res. 2007;39:91-8 [17314503.001]
  • [Cites] Med Hypotheses. 2006;67(1):33-5 [16516401.001]
  • [Cites] Thyroidology. 1989 Dec;1(3):105-8 [2484871.001]
  • [Cites] J Physiol Pharmacol. 1998 Jun;49(2):303-10 [9670113.001]
  • [Cites] Neuroscience. 1996 Aug;73(3):705-13 [8809792.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Aug;71(2):414-24 [2380337.001]
  • [Cites] Med Sci Monit. 2001 May-Jun;7(3):377-81 [11386012.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Jun;18(2):247-53 [10464715.001]
  • [Cites] Neurosci Res. 1999 Nov;35(2):145-53 [10616918.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Dec;36(12):2503-18 [15325588.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3017-24 [16303767.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):97-116 [15027888.001]
  • (PMID = 19381877.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / GABARAP protein, human; 0 / Microtubule-Associated Proteins; 0 / Receptors, GABA; 0 / Receptors, GABA-A; 0 / Receptors, GABA-B
  •  go-up   go-down


62. Tabriz HM, Adabi Kh, Lashkari A, Heshmat R, Haghpanah V, Larijani B, Tavangar SM: Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm. Pathol Res Pract; 2009;205(2):83-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
  • INTRODUCTION: We aimed at assessing the significance of nm23 gene expression in papillary and follicular carcinomas, the two most common differentiated thyroid carcinomas.
  • MATERIALS AND METHODS: During a cross-sectional study, 173 paraffin blocks, including 131 papillary thyroid carcinomas, 12 follicular carcinomas and 30 follicular adenomas were stained with nm23 marker by immunohistochemistry method.
  • RESULTS: nm23 was positive in 40% of the follicular adenoma, 67.2% of the papillary carcinoma and 66.7% of the follicular carcinoma. p value was more than 0.05 in the assessment of the relationship between nm23 and all of the above-mentioned parameters in differentiated thyroid carcinomas. nm23 expression did not significantly differentiate between follicular adenoma and carcinoma.
  • Also, nm23 cannot be considered as a useful marker for the evaluation of invasion in differentiated thyroid carcinomas or in distinctions between follicular adenoma and carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Papillary / metabolism. Adenoma / metabolism. NM23 Nucleoside Diphosphate Kinases / biosynthesis. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18996649.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NM23 Nucleoside Diphosphate Kinases; EC 2.7.4.6 / NME1 protein, human
  •  go-up   go-down


63. Laco J, Ryska A: [The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern]. Cesk Patol; 2006 Jul;42(3):120-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern].
  • The aim of the study was to evaluate the expression of galectin-3 (gal3), cytokeratin 19 (CK19), neural cell adhesion molecule (NCAM), and E-cadherin (Ecad) in thyroid gland tumors with follicular growth pattern with particular focus on their use in differential diagnosis.
  • A series of 139 cases - 87 follicular adenomas (FAs), 26 follicular carcinomas (FCs), and 26 cases of the follicular variant of papillary carcinoma (FVPC) was studied.
  • Therefore, the use of gal3 and CK19 in differential diagnosis of FVPC versus FA and FC can be recommended.
  • [MeSH-major] Biomarkers, Tumor / analysis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / chemistry. Adenoma / diagnosis. Adolescent. Adult. Aged. Aged, 80 and over. Cadherins / analysis. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary, Follicular / chemistry. Carcinoma, Papillary, Follicular / diagnosis. Diagnosis, Differential. Female. Galectin 3 / analysis. Humans. Immunohistochemistry. Keratins / analysis. Male. Middle Aged. Neural Cell Adhesion Molecule L1 / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955558.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Galectin 3; 0 / Neural Cell Adhesion Molecule L1; 68238-35-7 / Keratins
  •  go-up   go-down


64. Vecil GG, Papadopoulos NV, Vassilopoulou-Sellin R, McCutcheon IE: Interferon-induced hypothyroidism causing reversible pituitary enlargement. Endocr Pract; 2008 Mar;14(2):219-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After treatment with interferon for 1 year, persistent fatigue and menstrual irregularities led to the laboratory diagnosis of hypothyroidism, and magnetic resonance imaging revealed pituitary enlargement.
  • Both her endocrinopathy and the pituitary hyperplasia resolved with discontinuation of the interferon treatment and with institution of thyroid replacement therapy.
  • CONCLUSION: Clinicians should be aware of the potential adverse effects of interferon therapy to avoid inappropriate diagnosis of a pituitary adenoma or metastatic lesion in patients with cancer who are treated with interferon.
  • [MeSH-major] Hypothyroidism / chemically induced. Interferons / adverse effects. Pituitary Gland / drug effects

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308662.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9008-11-1 / Interferons
  •  go-up   go-down


65. Chan P, Mahler J, Travlos G, Nyska A, Wenk M: Induction of thyroid lesions in 14-week toxicity studies of 2 and 4-methylimidazole in Fischer 344/N rats and B6C3F1 mice. Arch Toxicol; 2006 Mar;80(3):169-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of thyroid lesions in 14-week toxicity studies of 2 and 4-methylimidazole in Fischer 344/N rats and B6C3F1 mice.
  • In the 15-day studies, 2MI induced thyroid follicular-cell hyperplasia and pituitary pars-distalis hypertrophy in rats and thyroid follicular-cell hypertrophy and spleen hematopoietic-cell proliferation in mice; 4MI induced no histopathological changes in rats and mice.
  • In the 14-week studies, 2MI increased concentrations of thyroid-stimulating hormone (TSH) and decreased those of thyroxine (T(4)) and triiodothyroxine (T(3)) in male and female rats according to the dosage.
  • Incidences of diffuse follicular-cell hyperplasia of the thyroid gland increased significantly in male rats exposed to 1,250 ppm or greater and female rats exposed to 2,500 ppm or greater.
  • Thyroid follicular-cell adenoma was diagnosed in two males in the 10,000-ppm group.
  • In mice, follicular-cell hypertrophy of the thyroid gland, anemia, splenic hematopoietic-cell proliferation, and hemosiderin in kidney tubules appeared.
  • Serum T(3), T(4), and TSH levels were not altered, and no thyroid lesions occurred.
  • Our studies demonstrated that, in rats and mice, 2MI induces thyroid hyperplasia and hypertrophy, and both 2MI and 4MI induce anemia; 2MI induces thyroid follicular-cell adenoma in male rats.
  • [MeSH-major] Imidazoles / toxicity. Thyroid Diseases / pathology. Toxicity Tests, Chronic / methods

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • Hazardous Substances Data Bank. 2-Methylimidazole .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16180012.001).
  • [ISSN] 0340-5761
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Imidazoles; 06LU7C9H1V / Triiodothyronine; 693-98-1 / 2-methylimidazole; Q51BO43MG4 / Thyroxine; Q64GF9FV4I / 4-methylimidazole
  •  go-up   go-down


66. Oh JG, Yoon CH, Lee CW: Case of Cowden syndrome associated with eccrine angiomatous hamartoma. J Dermatol; 2007 Feb;34(2):135-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cowden syndrome, also known as multiple hamartoma syndrome is a rare autosomal dominant disorder characterized by multiple hamartomatous tumors of ectodermal, mesodermal and endodermal origin.
  • Thyroid adenoma was diagnosed at age 46.
  • Histological examination of the skin lesion on the left foot showed an increased numbers of eccrine sweat glands and blood vessels, which are characteristic histological findings of eccrine angiomatous hamartoma (EAH), a rare benign tumor.
  • [MeSH-major] Eccrine Glands. Hamartoma Syndrome, Multiple / pathology. Hemangioma / pathology. Sweat Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Cowden Syndrome.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239153.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


67. Maji D: Hyperthyroidism. J Indian Med Assoc; 2006 Oct;104(10):563-4, 566-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyperthyroidism is a clinical situation where there is excess thyroid hormones in the circulation due to increased synthesis of hormone from a hyperactive thyroid gland.
  • Excess thyroid hormones in the circulation are also found in thyroiditis (hormone leakage) and excess exogenous thyroxine intake.
  • Thyrotoxicosis is the term applied when there is excess thyroid hormone in the circulation due to any cause.
  • Thyrotoxicosis can be easily diagnosed by high serum level of thyroxine (T4) and triiodothyronine (T3) and low serum level of thyroid stimulating hormone (TSH).
  • Hyperthyroidism is confirmed by high isotope (I 131 or Tc99) uptake by the thyroid gland, while in thyroiditis it will be low.
  • Surgery is the preferred treatment for toxic adenoma and toxic multinodular goitre, while 1131 therapy may be suitable in some cases.
  • [MeSH-major] Hyperthyroidism / diagnosis
  • [MeSH-minor] Graves Disease / physiopathology. Humans. Risk Factors. Thyrotoxicosis / diagnosis. Thyrotoxicosis / physiopathology

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17380820.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 11
  •  go-up   go-down


68. Shikama Y, Mizukami H, Sakai T, Yagihashi N, Okamoto K, Yagihashi S: Spindle cell metaplasia arising in thyroid adenoma: characterization of its pathology and differential diagnosis. J Endocrinol Invest; 2006 Feb;29(2):168-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle cell metaplasia arising in thyroid adenoma: characterization of its pathology and differential diagnosis.
  • Spindle cell metaplasia in thyroid adenoma or carcinoma is rare and its pathological features are not well characterized.
  • We encountered a case of thyroid follicular adenoma associated with spindle cell metaplasia.
  • It showed "tumor in tumor appearance" and neoplastic spindle cells were positive for thyroglobulin, thyroid transcription factor-1, vimentin and focally chromogranin A and somatostatin (SS).
  • Ultrastructure of the spindle cells was reminiscent of follicular cell origin.
  • From the findings from our case, spindle cell metaplasia appears to be a benign clinical entity, suggestive of multidirectional differentiation of follicular cells.
  • [MeSH-major] Adenoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Metaplasia / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2004 Jan;128(1):87-9 [14692805.001]
  • [Cites] Arch Pathol Lab Med. 1994 Nov;118(11):1143-7 [7979902.001]
  • [Cites] Am J Surg. 1965 Oct;110(4):660-8 [5825178.001]
  • [Cites] Semin Diagn Pathol. 2000 May;17(2):109-19 [10839611.001]
  • [Cites] Mod Pathol. 1997 May;10(5):510-4 [9160319.001]
  • [Cites] Am J Clin Pathol. 1985 Feb;83(2):135-58 [2578727.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):70-4 [9894456.001]
  • [Cites] Virchows Arch. 2005 Jan;446(1):91-2 [15517364.001]
  • [Cites] Am J Clin Pathol. 1991 Mar;95(3):309-14 [1996541.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1424-8 [11684960.001]
  • [Cites] Mod Pathol. 2003 Jan;16(1):43-8 [12527712.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):199-204 [11863215.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Apr;6(4):239-42 [7685628.001]
  • (PMID = 16610245.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


69. Xue WC, Hui YZ: [Problems in the diagnosis of thyroid papillary and follicular carcinoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Apr;36(4):220-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Problems in the diagnosis of thyroid papillary and follicular carcinoma].
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Humans. Neoplasm Invasiveness. Thyroid Gland / pathology. Thyroid Nodule / diagnosis. Thyroiditis / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706110.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


70. Hasegawa T, Araki A, Tamura Y, Sugawara T, Iwata A, Kamimiya F, Chiba Y, Horiuchi T, Mori S, Ito H: [A case of Plummer disease that appeared in older old age after 10-year course of subclinical hyperthyroidism]. Nihon Ronen Igakkai Zasshi; 2007 Mar;44(2):251-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 81-year-old woman with a thyroid tumor and subclinical hyperthyroidism since ten years ago was admitted to our hospital for palpitations and hyperthyroidism (FT(4) 1.75 ng/dl, FT(3) 5.37 pg/ml, TSH<0.03 microIU/ml).
  • Although thyroid stimulating antibody (TSAb) was transiently and mildly positive, anti-TSH receptor antibody (TRAb), microsome test, and thyroid test were negative.
  • Thyroid echogram showed an isoechoic nodule in the left lobe (33 x 42 x 22 mm) and a small nodule (10 x 15 x 9 mm) in right lobe.
  • Thyroid scintiscan showed a hyperfunctional (hot) nodule in left thyroid lobe with suppressed uptake in the remainder of the gland.
  • Based on the above findings, a diagnosis of Plummer disease was made.
  • After treatment with propranolol and thiamazole, the thyrotoxic symptoms disappeared and thyroid function returned to normal level.
  • [MeSH-major] Hyperthyroidism / complications. Hyperthyroidism / diagnosis
  • [MeSH-minor] Adenoma / complications. Aged, 80 and over. Antithyroid Agents / therapeutic use. Autoantibodies / blood. Female. Humans. Methimazole / therapeutic use. Osteoporosis, Postmenopausal / complications. Thyroid Nodule / complications. Thyrotropin / immunology

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • Hazardous Substances Data Bank. METHIMAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527029.001).
  • [ISSN] 0300-9173
  • [Journal-full-title] Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
  • [ISO-abbreviation] Nihon Ronen Igakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antithyroid Agents; 0 / Autoantibodies; 554Z48XN5E / Methimazole; 9002-71-5 / Thyrotropin
  •  go-up   go-down


71. Bradly DP, Reddy V, Prinz RA, Gattuso P: Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases. Surgery; 2009 Dec;146(6):1099-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases.
  • BACKGROUND: The frequency of incidental papillary carcinoma (IPC) has been reported to be between 4.6 % and 10% in operatively treated benign thyroid diseases.
  • This study reviews the occurrence of IPC in thyroid glands removed for benign disease at our institution.
  • METHODS: Six hundred and seventy-eight patients underwent partial or total thyroidectomy for benign thyroid diseases.
  • The incidence of IPC was compared among patients with Hashimoto's thyroiditis, multinodular goiter, follicular adenoma, and Graves' disease.
  • RESULTS: Overall, 81 (12.0%) IPCs were recorded with decreasing order of frequency: Hashimoto's thyroiditis, follicular adenoma, goiter, and Graves' disease.
  • Contralateral IPC was detected in 6/15 (40%) patients with follicular adenoma.
  • CONCLUSION: The overall incidence of IPC in benign operatively resected thyroid disease was 12%.
  • IPC was encountered in the contralateral lobe in 40% of patients with follicular adenoma.
  • The association of IPCs with Hashimoto's thyroiditis may indicate a link to thyroid cancer.
  • Total thyroidectomy may be considered an appropriate operative treatment in patients with Hashimoto's thyroiditis and follicular adenoma requiring operation owing to the high incidence and frequent contralateral involvement of IPC, respectively.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Thyroid Diseases / surgery. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Chicago / epidemiology. Female. Goiter, Nodular / complications. Goiter, Nodular / surgery. Graves Disease / complications. Graves Disease / surgery. Hashimoto Disease / complications. Hashimoto Disease / surgery. Humans. Male. Middle Aged. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Multiple Primary / surgery. Thyroidectomy. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958937.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Loffler KA, Biondi CA, Gartside M, Waring P, Stark M, Serewko-Auret MM, Muller HK, Hayward NK, Kay GF: Broad tumor spectrum in a mouse model of multiple endocrine neoplasia type 1. Int J Cancer; 2007 Jan 15;120(2):259-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we describe a mouse model of MEN1 in which tumors were seen in pancreatic islets, pituitary, thyroid and parathyroid, adrenal glands, testes and ovaries.
  • Menin expression was below the level of detection in ovary, thyroid and testis, but loss of nuclear menin immunoreactivity was observed uniformly in all pancreatic islet adenomas and in some hyperplastic islet cells, suggesting that complete loss of Men1 is a critical point in islet tumor progression in this model.
  • [MeSH-major] Adenoma / pathology. Disease Models, Animal. Endocrine Gland Neoplasms / pathology. Mice / genetics. Multiple Endocrine Neoplasia Type 1 / pathology. Proto-Oncogene Proteins / genetics


73. Steele SR, Martin MJ, Mullenix PS, Azarow KS, Andersen CA: The significance of incidental thyroid abnormalities identified during carotid duplex ultrasonography. Arch Surg; 2005 Oct;140(10):981-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of incidental thyroid abnormalities identified during carotid duplex ultrasonography.
  • HYPOTHESIS: Incidental thyroid masses identified during carotid duplex ultrasonography may represent clinically significant lesions.
  • INTERVENTIONS: After bilateral carotid duplex ultrasonography, selected patients additionally underwent 1 or more of the following: dedicated thyroid ultrasound, fine-needle aspiration biopsy, and/or partial or total thyroidectomy.
  • MAIN OUTCOME MEASURES: The prevalence and type of thyroid abnormalities, correlation with a dedicated thyroid ultrasound, and results of histopathologic diagnosis.
  • RESULTS: One or more thyroid abnormalities were identified in 188 duplexes (9.4%) involving 168 patients.
  • Sixty-six of the patients (40%) went on to have formal thyroid ultrasounds.
  • Surgical pathology included 5 patients with cancer (3 with papillary cancer, 2 with follicular cancer), 4 patients with a follicular adenoma, and 2 with lymphocytic thyroiditis).
  • Two additional patients were discovered to have parathyroid adenomas following further workup and surgery.
  • Thyroid abnormalities identified during carotid duplex ultrasonography correlated with formal ultrasound in 64 of 66 (97%) patients.
  • Measurement of the thyroid mass by carotid duplex strongly correlated with measurement by formal thyroid ultrasound (r = 0.95, P<.001).
  • Two patients with unilateral masses noted on carotid duplex had a normal thyroid formal ultrasound.
  • CONCLUSIONS: Incidental thyroid abnormalities identified during carotid duplex ultrasound are common and contain clinically significant pathology.
  • [MeSH-major] Carotid Artery Diseases / ultrasonography. Thyroid Neoplasms / ultrasonography
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Incidental Findings. Male. Middle Aged. Retrospective Studies. Thyroid Diseases / surgery. Thyroid Diseases / ultrasonography. Ultrasonography, Doppler, Duplex

  • MedlinePlus Health Information. consumer health - Carotid Artery Disease.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16230549.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Poggi M, Monti S, Pascucci C, Toscano V: A rare case of follicular thyroid carcinoma in a patient with thyrotropin-secreting pituitary adenoma. Am J Med Sci; 2009 Jun;337(6):462-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of follicular thyroid carcinoma in a patient with thyrotropin-secreting pituitary adenoma.
  • OBJECTIVE: To report a rare case of a thyrotropin (TSH)-secreting pituitary adenoma associated with thyroid carcinoma.
  • METHODS: We report the clinical history, imaging studies, and laboratory and pathologic data in a male patient affected by TSH-secreting pituitary adenoma and goiter; histologic evaluation revealed thyroid carcinoma.
  • The basal and dynamic hematologic evaluation showed the presence of high free thyroid hormone levels with inappropriate levels of TSH.
  • The thyroid morphologic study using Doppler ultrasonography showed a gland of increased volume with multiple nodular lesions bilaterally.
  • The nuclear magnetic resonance of the pituitary gland described a microadenoma.
  • The definitive thyroid histologic examination showed the presence of minimally invasive follicular carcinoma of 17 mm diameter.
  • The patient firmly refused surgical removal of the pituitary adenoma.
  • Twelve months later, the hematologic examinations showed normal thyroid hormone levels and a TSH of 6.97 uIU/mL.
  • CONCLUSION: The clinical association between thyroid carcinoma and TSH-producing adenoma is rare, with the removal of the pituitary lesion being mandatory.
  • [MeSH-major] Adenoma / complications. Pituitary Neoplasms / complications. Thyroid Neoplasms / complications. Thyrotropin / secretion

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19390430.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin
  •  go-up   go-down


75. Cassol CA, Guo M, Ezzat S, Asa SL: GNAq mutations are not identified in papillary thyroid carcinomas and hyperfunctioning thyroid nodules. Endocr Pathol; 2010 Dec;21(4):250-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GNAq mutations are not identified in papillary thyroid carcinomas and hyperfunctioning thyroid nodules.
  • Since these neoplasms share with thyroid carcinomas a high frequency of MAP kinase pathway-activating mutations, we hypothesized whether GNAq mutations could also play a role in the development of thyroid carcinomas.
  • Additionally, activating mutations of another subtype of G protein (GNAS1) are frequently found in hyperfunctioning thyroid adenomas, making it plausible that GNAq-activating mutations could also be found in some of these nodules.
  • To investigate thyroid papillary carcinomas and thyroid hyperfunctioning nodules for GNAq mutations in exon 5, codon 209, a total of 32 RET/PTC, BRAF, and RAS negative thyroid papillary carcinomas and 13 hyperfunctioning thyroid nodules were evaluated.
  • Although plausible, GNAq mutations seem not to play an important role in the development of thyroid follicular neoplasms, either benign hyperfunctioning nodules or malignant papillary carcinomas.
  • Our results are in accordance with the literature, in which no GNAq hotspot mutations were found in thyroid papillary carcinomas, as well as in an extensive panel of other tumors.
  • The molecular basis for MAP-kinase pathway activation in RET-PTC/BRAF/RAS negative thyroid carcinomas remains to be determined.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Papillary / genetics. GTP-Binding Protein alpha Subunits / genetics. Mutation. Thyroid Neoplasms / genetics. Thyroid Nodule / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2004 Sep;36(9):961-8 [15322542.001]
  • [Cites] Genomics. 1995 Dec 10;30(3):470-75 [8825633.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5230-4 [18719078.001]
  • [Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]
  • [Cites] PLoS One. 2009 Aug 31;4(8):e6833 [19718445.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4184-8 [9398737.001]
  • [Cites] J Biol Chem. 1992 Sep 15;267(26):18263-6 [1526966.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):599-602 [19078957.001]
  • [Cites] Mol Cell Biol. 1992 Oct;12(10):4687-93 [1328859.001]
  • [Cites] Acta Oncol. 2009;48(7):1082-4 [19551532.001]
  • [Cites] Thyroid. 2009 Aug;19(8):921-2 [19445628.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):292-306 [16557281.001]
  • (PMID = 20714830.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GNAQ protein, human; 0 / GTP-Binding Protein alpha Subunits; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gq-G11
  •  go-up   go-down


76. Blankenship DR, Chin E, Terris DJ: Contemporary management of thyroid cancer. Am J Otolaryngol; 2005 Jul-Aug;26(4):249-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contemporary management of thyroid cancer.
  • Thyroid cancer is a relatively common and frequently curable malignant neoplasm, accounting for nearly 2% of all new cancers diagnosed annually in the United States.
  • We sought to review the epidemiology and pathology of the several types of thyroid cancer and to present our evidence-based management algorithm.
  • In addition to reviewing well-established approaches to diagnosis and management, emphasis is placed on newer techniques, including minimally invasive thyroidectomy, molecular detection of disease propensity, and the use of recombinant thyrotropin prior to radioiodine ablation.
  • [MeSH-major] Thyroid Neoplasms
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / therapy. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / therapy. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / therapy. Biopsy, Fine-Needle. Carcinoma / diagnosis. Carcinoma / pathology. Carcinoma / therapy. Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / pathology. Carcinoma, Medullary / therapy. Evidence-Based Medicine. Humans. Lymphoma / diagnosis. Lymphoma / pathology. Lymphoma / therapy. Thyroid Gland / anatomy & histology. Thyroid Gland / embryology. Thyroid Gland / radionuclide imaging. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991091.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


77. Diaconescu MR, Glod M, Costea I, Palade M, Grigorovici M: [Reoperations of the thyroid gland]. Chirurgia (Bucur); 2007 May-Jun;102(3):297-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reoperations of the thyroid gland].
  • Reoperative thyroid surgery may be necessary in recurrent simple goiters, thyrotoxicosis and especially cancers of the thyroid gland.
  • The present series reviewed 33 cases representing 7.3 % from our experience consisting of 440 thyroid operations.
  • Eleven cases had benign lesions: eight with uni or bilateral nodular goiters and three thyrotoxicosis (two with Basedow-Graves'disease and one with toxic adenoma) for which nodulectomy, subtotal lobectomies or thyroidectomies were performed.
  • In twenty one cases the surgical indication was done for persistent or recurrent thyroid carcinomas (16 papillary, two follicular and one case each of medullary, anaplastic and malignant lymphoma).
  • Among these 6 patients underwent completion total thyroidectomies associated in 9 another patients with radical or modified neck dissection and in the 6 remaining cases conservative procedures (lobectomies, tumoral excision) of the gland or nodes were done.
  • Reoperative thyroid surgery constitute a valuable surgical procedure for persistence or recurrence of benign and especially malignant thyroid lesions but is associated with significant increased risk of functional and anatomic complications rate than those of the initial surgery.
  • [MeSH-major] Thyroid Diseases / surgery. Thyroidectomy
  • [MeSH-minor] Adult. Aged. Carcinoma / surgery. Endocrine Surgical Procedures. Female. Goiter, Nodular / surgery. Graves Disease / surgery. Humans. Male. Middle Aged. Reoperation. Retrospective Studies. Thyroid Neoplasms / surgery. Thyrotoxicosis / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687858.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


78. Zhang YW, Greenblatt DY, Repplinger D, Bargren A, Adler JT, Sippel RS, Chen H: Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid. Ann Surg Oncol; 2008 Oct;15(10):2842-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid.
  • BACKGROUND: Hürthle cell neoplasms (HCNs) are rare tumors of the thyroid gland.
  • The definitive treatment for Hürthle cell carcinoma (HCC) is total thyroidectomy, while thyroid lobectomy is adequate for Hürthle cell adenoma (HCA).
  • METHODS: Between May 1994 and January 2007, 1,199 patients underwent thyroid surgery at an academic medical center.
  • Medical records of 55 consecutive patients who underwent thyroid resections for the preoperative diagnosis of HCN were reviewed.
  • RESULTS: Of the 55 patients with HCN, 46 (84%) had adenomas and 9 (16%) had carcinomas.
  • Patients with carcinoma also had significantly larger thyroid nodules (4.5 +/- 0.7 cm versus 2.5 +/- 0.2 cm, P < 0.001).
  • All HCNs less than 2 cm in diameter were benign.
  • [MeSH-major] Adenoma / pathology. Adenoma, Oxyphilic / pathology. Neoplasm Recurrence, Local / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665423.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / T35 DK062709
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS778770; NLM/ PMC4852735
  •  go-up   go-down


79. Parenti G, Nassi R, Silvestri S, Bianchi S, Valeri A, Manca G, Mangiafico S, Ammannati F, Serio M, Mannelli M, Peri A: Multi-step approach in a complex case of Cushing's syndrome and medullary thyroid carcinoma. J Endocrinol Invest; 2006 Feb;29(2):177-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-step approach in a complex case of Cushing's syndrome and medullary thyroid carcinoma.
  • The diagnosis of Cushing's syndrome (CS) may sometimes be cumbersome.
  • In particular, in ACTH-dependent CS it may be difficult to distinguish between the presence of an ACTH-secreting pituitary adenoma and ectopic ACTH and/or CRH secretion.
  • We report here the case of a 54-yr-old man affected by ACTH-dependent CS in association with a left adrenal adenoma and medullary thyroid carcinoma (MTC).
  • It was then decided to remove the left adenomatous adrenal gland.
  • [MeSH-major] Carcinoma, Medullary / diagnosis. Cushing Syndrome / diagnosis. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Nucl Med. 1998 Jan;23 (1):13-5 [9442958.001]
  • [Cites] Q J Nucl Med. 1995 Dec;39(4 Suppl 1):13-6 [9002742.001]
  • [Cites] N Engl J Med. 1991 Sep 26;325(13):897-905 [1652686.001]
  • [Cites] Acta Endocrinol (Copenh). 1988 Dec;119(4):506-16 [3264436.001]
  • [Cites] Lancet. 2001 Mar 10;357(9258):783-91 [11253984.001]
  • [Cites] J Endocrinol Invest. 2000 Sep;23(8):536-41 [11021771.001]
  • [Cites] Clin Nucl Med. 1994 Dec;19(12 ):1066-8 [7874804.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):1029-35 [12629081.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10 ):4565-8 [14557423.001]
  • [Cites] Eur J Endocrinol. 2001 Nov;145(5):605-11 [11720879.001]
  • [Cites] Endocr Rev. 1994 Dec;15(6):752-87 [7705280.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4616-22 [14557431.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10 ):4754-8 [14557451.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Apr;52(4):427-35 [10762285.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):5593-602 [14671138.001]
  • [Cites] Ann Endocrinol (Paris). 1988;49(1):61-7 [3261569.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):305-8 [9467532.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Nov;130(11):649-56 [15300425.001]
  • [Cites] N Engl J Med. 1998 Sep 24;339(13):883-6 [9744972.001]
  • [Cites] Clin Endocrinol (Oxf). 1978 Sep;9(3):221-6 [213218.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):487-92 [10022405.001]
  • [Cites] Hum Pathol. 1992 May;23(5):592-6 [1568756.001]
  • [Cites] N Engl J Med. 1995 Mar 23;332(12):791-803 [7862184.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):440-8 [10022398.001]
  • [Cites] Panminerva Med. 1996 Mar;38(1):41-4 [8766879.001]
  • [Cites] Microsc Res Tech. 2003 Jun 15;61(3):308-14 [12768546.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4771-5 [11134141.001]
  • [Cites] Eur J Endocrinol. 2002 Feb;146(2):237-40 [11834434.001]
  • (PMID = 16610247.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 9007-12-9 / Calcitonin
  •  go-up   go-down


80. Haddy N, Andriamboavonjy T, Paoletti C, Dondon MG, Mousannif A, Shamsaldin A, Doyon F, Labbé M, Robert C, Avril MF, Fragu P, Eschwege F, Chavaudra J, Schvartz C, Lefkopoulos D, Schlumberger M, Diallo I, de Vathaire F: Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy. Radiother Oncol; 2009 Nov;93(2):377-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy.
  • This paper presents the incidence of differentiated thyroid adenomas and carcinomas after radiotherapy in this cohort.
  • The radiation dose received by the thyroid during radiotherapy, estimated in 3497 of the 3795 patients using specific software, was 41 mGy on average.
  • Thyroid tumor cases were obtained by sending out a questionnaire, and were verified in pathological reports.
  • Estimates of thyroid cancer specific incidence rates in the French population were obtained from the French cancer registry network.
  • RESULTS: During an average follow-up of 35 years, 11 patients developed a differentiated thyroid carcinoma and 44 a thyroid adenoma.
  • The incidence of thyroid adenoma was found to be higher among taller and heavier individuals.
  • The incidence of both thyroid carcinoma and adenoma was higher among non-smoker patients.
  • A significant dose-response relationship was found between the radiation dose received by thyroid and the risk of thyroid cancer (Excess Relative Risk per GY, ERR/Gy: 14.7, 95%CI: 1.6-62.9) and of adenoma (ERR/Gy: 5.7, 95%CI: 0.7-19.4).
  • CONCLUSION: This study confirms that radiation treatment performed in the past for hemangioma during infancy increased the risk of thyroid carcinoma and adenoma.
  • Patients treated with external radiotherapy or with Radium 226 applicators for hemangiomas have to be more specifically followed up because this is the subgroup in whom the highest doses were received by the thyroid gland (more than 90% of the radiation doses were higher than 100 mGy).
  • They are therefore more at risk of developing thyroid cancer.
  • [MeSH-major] Hemangioma / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Thyroid Neoplasms / etiology


81. Zablotska LB, Bogdanova TI, Ron E, Epstein OV, Robbins J, Likhtarev IA, Hatch M, Markov VV, Bouville AC, Olijnyk VA, McConnell RJ, Shpak VM, Brenner A, Terekhova GN, Greenebaum E, Tereshchenko VP, Fink DJ, Brill AB, Zamotayeva GA, Masnyk IJ, Howe GR, Tronko MD: A cohort study of thyroid cancer and other thyroid diseases after the Chornobyl accident: dose-response analysis of thyroid follicular adenomas detected during first screening in Ukraine (1998-2000). Am J Epidemiol; 2008 Feb 1;167(3):305-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cohort study of thyroid cancer and other thyroid diseases after the Chornobyl accident: dose-response analysis of thyroid follicular adenomas detected during first screening in Ukraine (1998-2000).
  • The Chornobyl (Chernobyl) accident in 1986 exposed many individuals to radioactive iodines, chiefly (131)I, the effects of which on benign thyroid diseases are largely unknown.
  • To investigate the risk of follicular adenoma in relation to radiation dose after Chornobyl, the authors analyzed the baseline data from a prospective screening cohort study of those exposed as children or adolescents.
  • A stratified random sample was selected from all individuals who were younger than 18 years, had thyroid radioactivity measurements taken within 2 months after the accident, and resided in the three heavily contaminated areas in Ukraine.
  • This analysis is based on the 23 cases diagnosed in 12,504 subjects for whom personal history of thyroid diseases was known.
  • In conclusion, persons exposed to radioactive iodines as children and adolescents have an increased risk of follicular adenoma, though it is smaller than the risk of thyroid cancer in the same cohort.
  • [MeSH-major] Adenoma / etiology. Neoplasms, Radiation-Induced / epidemiology. Thyroid Neoplasms / etiology


82. Cerutti JM, Latini FR, Nakabashi C, Delcelo R, Andrade VP, Amadei MJ, Maciel RM, Hojaij FC, Hollis D, Shoemaker J, Riggins GJ: Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clin Cancer Res; 2006 Jun 1;12(11 Pt 1):3311-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of suspicious thyroid nodules using four protein biomarkers.
  • PURPOSE: Fine-needle aspiration (FNA) cytology, a standard method for thyroid nodule diagnosis, cannot distinguish between benign follicular thyroid adenoma (FTA) and malignant follicular thyroid carcinoma (FTC).
  • The goal of this study was to determine if antibody markers used alone or in combination could accurately distinguish between a wider variety of benign and malignant thyroid lesions in fixed sections and FNA samples.
  • EXPERIMENTAL DESIGN: Immunohistochemistry was done on 27 FTA, 25 FTC, and 75 other benign and malignant thyroid tissue sections using custom antibodies for chromosome 1 open reading frame 24 (C1orf24) and integral membrane protein 1 (ITM1) and commercial antibodies for DNA damage-inducible transcript 3 (DDIT3) and arginase II (ARG2).
  • RNA expression was measured by quantitative PCR in 33 thyroid lesions.
  • CONCLUSIONS: We improved this diagnostic test by adding C1orf24 and ITM1 custom antibodies and showing use on a wider variety of thyroid pathology.
  • Use of one or more of these antibodies should improve diagnostic accuracy of suspicious thyroid nodules from both tissue sections and FNA samples.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenoma / diagnosis. Biomarkers, Tumor / analysis. Immunohistochemistry / methods. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740752.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA113461; United States / PHS HHS / / S98-146
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / DDIT3 protein, human; 0 / FAM129A protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 147336-12-7 / Transcription Factor CHOP; EC 2.4.1.- / Hexosyltransferases; EC 2.4.99.18 / STT3A protein, human; EC 3.5.3.1 / Arginase; EC 3.5.3.1 / arginase II, human
  •  go-up   go-down


83. Pisello F, Geraci G, Sciumè C, Li Volsi F, Modica G: [Total thyroidectomy of choice in papillary microcarcinoma]. G Chir; 2007 Jan-Feb;28(1-2):13-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La tiroidectomia totale di principio nel microcarcinoma papillare.
  • INTRODUCTION: Today, the "gold standard" of surgical management of benign thyroid disease is still controversy.
  • There are different surgical approaches to the thyroid gland, from a radical, total thyroidectomy to a conservative treatment, lobectomy with or not isthmectomy.
  • In consideration of the more frequent incidence of small carcinomas accidentally founded in the context of the thyroid parenchyma removed for another pathology, the aim of this study is to bring a contribute to resolve the debate on the therapeutic choice in the surgical management of the thyroid benign disease.
  • PATIENTS AND METHODS: From January 2000 to January 2006 502 thyroidectomy were performed in the Section of General and Thoracic Surgery of University of Palermo: 458 total thyroidectomy (91.3%), 2 partial thyroidectomy (0.3%), 24 (4.8%) lobectomy with isthmectomy and 18 (3.6%) reinterventions for relapse; 34 patients (6.8%) were preoperative suspected (cytological or ultrasonography) for thyroid cancer.
  • Histologically, were 11 cases of classical papillary (64.7%), 4 cases (23.6%) of follicular and 2 (11.7%) sclerosing, in 9 cases of multinodular goiter, 3 of follicular adenoma, 3 cases of follicular carcinoma, 1 case of Graves disease and 1 case of Hashimoto thyroiditis.
  • DISCUSSION: Papillary microcarcinoma is a "thyroid papillary cancer with a diameter < or = 1 cm? ".
  • CONCLUSIONS: In our opinion, the surgical management of the all thyroid disease must be the more radical since the first time, because we think other approaches not correct to improve the complete health from the benign thyroid disease and to prevent (secondary prevention) papillary microcarcinoma not pre-operative diagnosed, because there are no preoperative pattern to make a correct diagnosis of this tumour.
  • [MeSH-major] Carcinoma, Papillary / surgery. Thyroid Neoplasms / surgery. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313727.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


84. van den Bergh AC, van den Berg G, Schoorl MA, Sluiter WJ, van der Vliet AM, Hoving EW, Szabó BG, Langendijk JA, Wolffenbuttel BH, Dullaart RP: Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys; 2007 Mar 1;67(3):863-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy.
  • PURPOSE: To demonstrate the benefit of immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma (NFA) in perspective to the need for hormonal substitution and life expectancy.
  • There were no differences between Group 1 and 2 regarding the need for substitution with thyroid hormone, glucocorticoids, and sex hormones before first surgery, directly after surgery and at end of follow-up.
  • [MeSH-major] Adenoma / radiotherapy. Life Expectancy. Pituitary Gland / radiation effects. Pituitary Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197121.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Seimiya YM, Takahashi M, Furukawa T, Mizutani K, Kimura K, Haritani M: An aged bull with concurrent thyroid C cell carcinoma, adrenal pheochromocytoma and pituitary chromophobe adenoma. J Vet Med Sci; 2009 Feb;71(2):225-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An aged bull with concurrent thyroid C cell carcinoma, adrenal pheochromocytoma and pituitary chromophobe adenoma.
  • Pathological examination disclosed multiple endocrine tumors including thyroid C cell carcinoma with metastases to the cervical lymph nodes and lung, adrenal pheochromocytoma and pituitary chromophobe adenoma in the pars distalis.
  • The long-term dietary intake of moderately excessive calcium with vitamin D(3) might be related to the pathogenesis of the thyroid C cell carcinoma.


86. Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N, Smit JW: Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol; 2008 Mar;158(3):375-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
  • OBJECTIVES: The microscopic distinction between benign and malignant thyroid lesions in clinical practice is still largely based on conventional histology.
  • This study was performed to evaluate the diagnostic value of galectin-3 (Gal-3), Hector Battifora mesothelial-1 (HBME-1), cytokeratin (CK)-19, CBP P300-interacting transactivator with glutamic acid E- and aspartic acid D-rich C-terminal domain (CITED-1), fibronectin (FN)-1, peroxisome proliferator-activated receptor (PPAR)-gamma, and intracellular sodium/iodide symporter (iNIS) immunostaining in a large panel of thyroid neoplasms.
  • METHODS: We used tissue arrays containing 177 thyroid tissues: 100 benign tissues (including normal thyroid, Graves disease, multinodular goiter, and follicular adenoma (FA)) and 77 thyroid carcinomas (including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma, and follicular variant of PTC (FVPTC)).
  • RESULTS: In general, we found overexpression of FN-1, CITED-1, Gal-3, CK-19, HBME-1, and iNIS in malignant thyroid lesions.
  • Gal-3, FN-1, and iNIS had the highest accuracy in the differential diagnosis of follicular lesions.
  • A panel of Gal-3, FN-1, and iNIS, identified by hierarchical cluster analysis, had a 98% accuracy to differentiate between FA and malignant thyroid lesions.
  • CONCLUSION: We conclude that identifying optimal antibody panels with cluster analysis increases the diagnostic value in the differential diagnosis of thyroid neoplasms, the combination of FN-1, Gal-3, and iNIS having the best accuracy (98%).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299472.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / CITED1 protein, human; 0 / Fibronectins; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19; 0 / Nuclear Proteins; 0 / PPAR gamma; 0 / Symporters; 0 / Transcription Factors; 0 / sodium-iodide symporter
  •  go-up   go-down


87. Weismann D, Fassnacht M, Schubert B, Bonfig R, Tschammler A, Timm S, Hahner S, Wunder C, Allolio B: A dangerous liaison--pheochromocytoma in patients with malignant disease. Ann Surg Oncol; 2006 Dec;13(12):1696-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite improved imaging techniques, it remains difficult to distinguish an adrenal metastasis from a pheochromocytoma or a lipid-poor adrenocortical adenoma.
  • PATIENTS AND METHODS: We report a case series of four patients with established or suspected malignant disease (melanoma, transitional cell carcinoma and prostate carcinoma, thyroid carcinoma, colorectal carcinoma) harboring an adrenal mass.
  • CONCLUSION: Our series is a strong reminder of the risks associated with surgery in patients harboring an unsuspected pheochromocytoma and underscores the need to exclude a pheochromocytoma in all patients with an adrenal mass and without a definitive diagnosis of the mass, especially when they are scheduled for surgery or adrenal biopsy.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Neoplasms, Second Primary / pathology. Pheochromocytoma / diagnosis. Prostatic Neoplasms / pathology. Skin Neoplasms / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / therapy. Humans. Male. Melanoma / pathology. Melanoma / therapy. Middle Aged


88. Zajícková K: [Primary hyperparathyroidism as a cause of hypercalcemia in a patient with breast cancer]. Cas Lek Cesk; 2010;149(11):546-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parathyroid gland scintigraphy revealed a possible parathyroid adenoma behind the lower pole of the left thyroid lobe.
  • Microscopic examination identified a benign adenomatous goitre and benign parathyroid adenoma.
  • [MeSH-major] Adenoma / complications. Breast Neoplasms / complications. Carcinoma, Ductal, Breast / complications. Hypercalcemia / etiology. Hyperparathyroidism, Primary / complications. Neoplasms, Multiple Primary. Parathyroid Neoplasms / complications


89. Nucera C, Mazzon E, Caillou B, Violi MA, Moleti M, Priolo C, Sturniolo G, Puzzolo D, Cavallari V, Trimarchi F, Vermiglio F: Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia. J Endocrinol Invest; 2005 Feb;28(2):106-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia.
  • Increasing hgal-3 immunoexpression has been reported in several human tumors, including thyroid carcinomas, but not in benign thyroid lesions.
  • We analyzed the immunolocalization of hgal-3 in cell compartments of benign and malignant thyroid lesions.
  • Hgal-3 immunoperoxidase reaction was carried out on 133 thyroid tissue samples obtained from 113 patients; 20 of these were normal (NT), 85 were benign thyroid lesions [20 colloid nodules (CN), 21 nodular hyperplasias (NH), 7 focal lymphocytic thyroiditis (FLT), 15 Hashimoto's thyroiditis (HT), 22 follicular adenomas (FA)], 25 differentiated carcinomas [15 papillary carcinomas (PC), 6 follicular carcinomas (FC) and 4 Hürthle cell carcinomas (HC)] and 3 anaplastic carcinomas (AC).
  • Among the malignant thyroid lesions, hgal-3 was detected in 12/15 (80%) PC, 3/4 (75%) HC and in 4/6 (66.6%) FC, but in none of the 3 AC.
  • Conversely, hgal-3 immunoexpression was absent in NT and in all benign thyroid lesions, but 1/15 HT and 10/22 (45.4%) FA.
  • Hgal-3 cytoplasmic-perinuclear immunolocalization was observed in the majority of thyroid carcinomas and in more than half of the FA, theoretically suggesting an involvement of this protein in thyroid tumorigenesis throughout an antiapoptotic activity.
  • Moreover, hgal-3 expression in FA might anticipate the likelihood of evolution of these benign lesions towards malignancy.
  • [MeSH-major] Adenoma / chemistry. Adenoma / pathology. Galectin 3 / analysis. Thyroid Neoplasms / chemistry. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Immunohistochemistry / methods. Middle Aged. Staining and Labeling. Thyroid Diseases / metabolism. Thyroid Diseases / pathology. Thyroid Gland / chemistry. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1213-7 [7862663.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):449-53 [14585093.001]
  • [Cites] Thyroid. 2003 Aug;13(8):765-70 [14558920.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] Biochemistry. 1994 Nov 29;33(47):14109-14 [7947821.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):361-7 [10956411.001]
  • [Cites] J Pathol. 1997 Jan;181(1):80-6 [9072007.001]
  • [Cites] Invasion Metastasis. 1997;17(2):101-12 [9561029.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):494-8 [12657934.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Cancer Lett. 2003 Sep 10;199(1):69-73 [12963125.001]
  • [Cites] Mod Pathol. 2003 Nov;16(11):1117-23 [14614051.001]
  • [Cites] J Biol Chem. 1994 Aug 19;269(33):20807-10 [8063692.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):428-33 [10821488.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2637-41 [9703921.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):181-183 [11493987.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1869-73 [11280740.001]
  • [Cites] J Biol Chem. 1994 Feb 11;269(6):4424-30 [8308013.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2818-26 [7773932.001]
  • [Cites] Int J Oncol. 2001 Apr;18(4):787-92 [11251175.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):710-3 [12033961.001]
  • [Cites] Anat Rec. 1995 Jun;242(2):211-9 [7668406.001]
  • [Cites] Mod Pathol. 1997 May;10(5):515-9 [9160320.001]
  • [Cites] Endocr Pathol. 2001 Fall;12(3):275-9 [11740048.001]
  • [Cites] Virchows Arch. 2004 Apr;444(4):309-12 [14999471.001]
  • [Cites] Exp Cell Res. 1995 Oct;220(2):397-406 [7556449.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6239-45 [10626818.001]
  • [Cites] Histopathology. 2002 Jan;40(1):80-7 [11903601.001]
  • [Cites] J Biol Chem. 2002 May 3;277(18):15819-27 [11839755.001]
  • [Cites] Biochem Soc Trans. 1992 May;20(2):269-74 [1397610.001]
  • [Cites] J Endocrinol Invest. 2004 Apr;27(4):311-7 [15233548.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 14;302(3):545-53 [12615069.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3494-502 [10550147.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4530-4 [8813152.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2475-84 [10357421.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3015-20 [9679965.001]
  • (PMID = 15887854.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Galectin 3
  •  go-up   go-down


90. Rasmuson T, Tavelin B: Risk of parathyroid adenomas in patients with thyrotoxicosis exposed to radioactive iodine. Acta Oncol; 2006;45(8):1059-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of parathyroid adenomas in patients with thyrotoxicosis exposed to radioactive iodine.
  • Patients with thyrotoxicosis are often treated with radioactive iodine and its accumulation in the thyroid gland exposes the adjacent parathyroid glands to radioactivity.
  • Patients with parathyroid adenomas (ICD-9 = 195.1) were recruited from the Swedish Cancer Registry.
  • Eleven patients with parathyroid adenomas following the diagnosis of thyrotoxicosis were identified.
  • The median age at exposure was 59 years and the latency period between diagnosis of thyrotoxicosis and parathyroid adenoma was 7.4 years (range <1-19 years).
  • This study does not indicate that patients with thyrotoxicosis treated with radioactive iodine in adult age have increased risk of developing parathyroid adenoma.
  • [MeSH-major] Adenoma / etiology. Iodine Radioisotopes / adverse effects. Parathyroid Neoplasms / etiology. Thyrotoxicosis / radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118839.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


91. Kim SC, Kim S, Inabnet WB, Krynyckyi BR, Machac J, Kim CK: Appearance of descended superior parathyroid adenoma on SPECT parathyroid imaging. Clin Nucl Med; 2007 Feb;32(2):90-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appearance of descended superior parathyroid adenoma on SPECT parathyroid imaging.
  • An ectopic superior parathyroid adenoma (SPA) descends inferoposteriorly and can migrate to the posterior mediastinum.
  • METHODS: Sestamibi SPECT imaging studies performed on 103 patients who had parathyroid adenomas with their origin and locations confirmed by surgery and histology were retrospectively reviewed.
  • Abnormal foci seen on the SPECT images were grouped as to location relative to the thyroid gland as superior (S), middle (M), and inferior (I).
  • The proximity between the focus and the thyroid on the sagittal SPECT images was graded from 0 to 2 with 2 being widely separated.
  • Ten foci were at the M level, including 6 SPA and 4 inferior parathyroid adenomas (IPA).
  • There were 68 foci at the I level; none (0%) of 56 in the I0 location, 2 (25%) of 8 foci in the I1 location, and all (100%) of 4 abnormal foci in the I2 location were descended SPAs.
  • [MeSH-major] Adenoma / pathology. Adenoma / radionuclide imaging. Parathyroid Neoplasms / pathology. Parathyroid Neoplasms / radionuclide imaging. Tomography, Emission-Computed, Single-Photon

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17242559.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Lo CY, Lam KY, Leung PP, Luk JM: High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma. Eur J Endocrinol; 2005 Apr;152(4):545-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma.
  • BACKGROUND: Cyclooxygenase-2 (COX-2) seems to play a role in the development and carcinogenesis of papillary thyroid carcinoma.
  • MATERIALS AND METHODS: Immunohistochemical staining for COX-2 expression was performed for 30 papillary thyroid carcinoma (PTC) and 40 benign thyroid specimens.
  • RESULTS: COX-2 expression was detected by immunohistochemistry in 27 of 30 (90%) PTC but was absent in 40 benign thyroid specimens, including 27 nodular hyperplasia, 7 follicular adenoma and 6 lymphocytic thyroiditis.
  • Two of the three COX-2 negative carcinomas were follicular variant of PTC.
  • Real-time quantitative RT-PCR showed that the level of COX-2 mRNA expression was significantly higher in PTC than in both the adjacent non-cancerous tissues and the benign thyroid specimens.
  • CONCLUSION: COX-2 is frequently expressed in PTC but not in benign thyroid specimens.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15817909.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RNA, Messenger; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


93. Banito A, Pinto AE, Espadinha C, Marques AR, Leite V: Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours. Clin Endocrinol (Oxf); 2007 Nov;67(5):706-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
  • OBJECTIVE: Follicular thyroid tumours present several genetic alterations such as aneuploidy, RAS mutations and PAX8/PPARgammarearrangements.
  • The aim of our study was to investigate the correlation between aneuploidy, RAS mutations and PAX8/PPARgamma gene rearrangement in thyroid follicular tumours.
  • DESIGN: Ploidy status was determined by flow cytometry in 111 thyroid lesions (42 follicular thyroid adenomas, 27 follicular thyroid carcinomas, 19 follicular variants of papillary thyroid carcinoma, 20 poorly differentiated thyroid carcinomas and 3 anaplastic thyroid carcinomas).
  • The aneuploid tumours harbouring RAS mutations were two poorly differentiated carcinomas and one follicular variant of papillary thyroid carcinoma with poorly differentiated areas.
  • Three of five (60%) follicular thyroid adenomas and 1 of 7 (14%) follicular thyroid carcinomas, with the PAX8/PPARgamma fusion gene, were aneuploid.
  • CONCLUSIONS: Our data suggest that aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenoma / genetics. Aneuploidy. Genes, ras. Point Mutation. Thyroid Neoplasms / genetics
  • [MeSH-minor] Carcinoma / genetics. Carcinoma, Papillary, Follicular / genetics. DNA Mutational Analysis. Flow Cytometry. Gene Rearrangement. Humans. Oncogene Proteins, Fusion. PPAR gamma / genetics. Paired Box Transcription Factors / genetics. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651453.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors
  •  go-up   go-down


94. Asioli S, Bussolati G: Emerin immunohistochemistry reveals diagnostic features of nuclear membrane arrangement in thyroid lesions. Histopathology; 2009 Apr;54(5):571-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerin immunohistochemistry reveals diagnostic features of nuclear membrane arrangement in thyroid lesions.
  • AIMS: Objective appreciation of irregularities of the nuclear shape is a key parameter in the diagnosis of thyroid lesions, since foldings of the nuclear membrane (NM) featuring indentations, grooves and pseudoinclusions characterize papillary thyroid carcinomas (PTC).
  • METHODS AND RESULTS: Immunohistochemistry of the NM with emerin as well as three-dimensional reconstruction of the images (through deconvolution processing) performed on a series of 54 cases (processed following the tissue array procedure) revealed a uniform arrangement of the NM in non-neoplastic lesions (thyroiditis, microfollicular goitre, follicular adenoma) and normal thyroid as well as in follicular carcinoma.
  • CONCLUSIONS: Decoration of the NM represents an original approach to identify PTC nuclear shape, highlights new structural features and might be helpful in the differential diagnosis between so-called nuclear pseudoinclusions and artefactual 'bubbles'.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Nuclear Envelope / pathology. Thyroid Diseases / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Fluorescent Antibody Technique. Humans. Image Interpretation, Computer-Assisted. Immunohistochemistry. Membrane Proteins. Nuclear Proteins. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302538.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Nuclear Proteins; 0 / emerin
  •  go-up   go-down


95. Guerra LN, Miler EA, Moiguer S, Karner M, Orlandi AM, Fideleff H, Burdman JA: Telomerase activity in fine needle aspiration biopsy samples: application to diagnosis of human thyroid carcinoma. Clin Chim Acta; 2006 Aug;370(1-2):180-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity in fine needle aspiration biopsy samples: application to diagnosis of human thyroid carcinoma.
  • BACKGROUND: The diagnosis of thyroid follicular carcinoma by fine needle aspiration biopsy is a well known problem in thyroid pathology.
  • METHODS: We evaluated telomerase activity (TA) in 85 fine needle aspiration biopsy (FNAB) samples from patients with thyroid nodules.
  • Surgery samples from patients with tumor or follicular adenomas were also analyzed.
  • Among them, 4 follicular carcinomas and 1 papillary carcinoma were labeled as indeterminate by FNAB cytological examination.
  • FNAB samples from follicular adenomas were diagnosed as indeterminate by cytological examination, but they showed no detectable TA.
  • Tumor tissues from patients with follicular or papillary thyroid carcinomas presented TA >10 Units, whereas follicular adenoma tissues (benign nodules) showed no TA.
  • CONCLUSION: Our results showed a good correlation between TA in FNAB samples and tumor/nodule thyroid tissue.
  • This suggested that use of TA as a biological marker of malignancy might be a useful tool in the diagnosis of follicular thyroid carcinomas or follicular thyroid adenomas using FNAB samples.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Telomerase / metabolism. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Chim Acta. 2007 Sep;384(1-2):188
  • (PMID = 16600201.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


96. Drieschner N, Belge G, Rippe V, Meiboom M, Loeschke S, Bullerdiek J: Evidence for a 3p25 breakpoint hot spot region in thyroid tumors of follicular origin. Thyroid; 2006 Nov;16(11):1091-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for a 3p25 breakpoint hot spot region in thyroid tumors of follicular origin.
  • Epithelial tumors of the thyroid are cytogenetically well-investigated tumors.
  • Recently, we have been able to describe the involvement of a novel gene called THADA in benign thyroid lesions with 2p21 rearrangements.
  • Other fusion genes found in thyroid lesions are RET/PTC and PAX8/PPAR(gamma).
  • The latter occurs in follicular thyroid carcinomas with a t(2;3)(q13;p25).
  • Here we present molecular-cytogenetic and cytogenetic investigations on a follicular thyroid adenoma with a t(2;20;3)(p21;q11.2; p25).
  • Our findings suggest that the close surrounding of PPAR(gamma) is a breakpoint hot spot region, leading to recurrent alterations of this gene in thyroid tumors of follicular origin including carcinomas as well as adenomas with or without involvement of PAX8.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Chromosome Breakage. Neoplasm Proteins / genetics. PPAR gamma / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123335.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / PPAR gamma; 0 / THADA protein, human
  •  go-up   go-down


97. Turnbull MM, Humeniuk V, Stein B, Suthers GK: Arteriovenous malformations in Cowden syndrome. J Med Genet; 2005 Aug;42(8):e50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical features include trichilemmomas, verrucose lesions of the skin, macrocephaly, intellectual disability, cerebellar gangliocytoma, thyroid adenomas, fibroadenomas of the breast, and hamartomatous colonic polyps.
  • A family is described with a clinical diagnosis of Cowden syndrome, a familial frameshift mutation in the PTEN gene, and large visceral arteriovenous malformations.
  • Recognition of arteriovenous malformations as a clinical feature of Cowden syndrome has implications for the clinical management of patients with this disorder.
  • [MeSH-major] Arteriovenous Malformations / diagnosis. Hamartoma Syndrome, Multiple / diagnosis

  • Genetic Alliance. consumer health - Cowden Syndrome.
  • MedlinePlus Health Information. consumer health - Arteriovenous Malformations.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061556.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 153480/ 158350
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC1736111
  •  go-up   go-down


98. Verburg FA, de Keizer B, van Isselt JW: Use of radiopharmaceuticals for diagnosis, treatment, and follow-up of differentiated thyroid carcinoma. Anticancer Agents Med Chem; 2007 Jul;7(4):399-409
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of radiopharmaceuticals for diagnosis, treatment, and follow-up of differentiated thyroid carcinoma.
  • At the time, the histologic diagnosis was a 'malignant adenoma' of the thyroid.
  • In 1938 the patient returned with overt signs of thyroid hyperfunction (hyperthyroidism) and lower back pain.
  • In 1937 Hertz, Roberts and Evans investigated the rabbit's thyroid function using I-128 [2].
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Medical Oncology / methods. Radiopharmaceuticals / therapeutic use. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy
  • [MeSH-minor] Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Female. History, 20th Century. Humans. Male. Models, Biological. Models, Chemical. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Thyroid Gland / cytology. Thyroid Hormones / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17630916.001).
  • [ISSN] 1871-5206
  • [Journal-full-title] Anti-cancer agents in medicinal chemistry
  • [ISO-abbreviation] Anticancer Agents Med Chem
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Thyroid Hormones
  • [Number-of-references] 207
  •  go-up   go-down


99. Daousi C, Foy PM, MacFarlane IA: Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours. J Neurol Neurosurg Psychiatry; 2007 Jan;78(1):93-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours.
  • BACKGROUND: Thyrotropin (TSH)-secreting pituitary adenomas (TSHomas) are rare tumours that can be invasive.
  • It has been suggested that thyroid surgery or radioiodine treatment should not be considered in patients with such tumours as these treatments may facilitate rapid and aggressive tumour expansion.
  • AIM: To study the effects of thyroid ablative treatment on tumour size and thyroid status in two patients with TSHomas in whom the size of the adenoma was clearly documented before treatment was started.
  • CONCLUSIONS: Ablative thyroid treatment can be a safe and successful option to treat TSHomas, but long-term and close follow-up of these patients is mandatory to ensure that the size and behaviour of the tumours do not change markedly.
  • [MeSH-major] Pituitary Neoplasms / complications. Thyroid Gland / surgery. Thyrotoxicosis / etiology. Thyrotoxicosis / surgery. Thyrotropin / secretion

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1487-91 [10770186.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):476-86 [10022404.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2849-53 [11397898.001]
  • [Cites] Acta Endocrinol (Copenh). 1982 Feb;99(2):224-31 [6277128.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Nov;59(5):817-24 [6480809.001]
  • [Cites] J Endocrinol Invest. 1984 Aug;7(4):313-7 [6438219.001]
  • [Cites] N Engl J Med. 1987 Jul 2;317(1):12-7 [2884564.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jan;68(1):208-14 [2491862.001]
  • [Cites] Mol Cell Endocrinol. 1993 Feb;91(1-2):75-81 [8472856.001]
  • [Cites] Ann Intern Med. 1993 Aug 1;119(3):236-40 [8323093.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Feb;40(2):275-8 [7511073.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Mar;40(3):421-8 [8187308.001]
  • [Cites] Eur J Endocrinol. 1994 Jun;130(6):559-64 [8205254.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] Thyroid. 2000 Nov;10(11):1001-7 [11128714.001]
  • (PMID = 17172570.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin
  • [Other-IDs] NLM/ PMC2117800
  •  go-up   go-down


100. Ouyang D, Chen FJ, Wei MW, Yang AK, Chen ZQ, Li QL, Chen YF: [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma]. Ai Zheng; 2005 Nov;24(11):1367-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma].
  • BACKGROUND & OBJECTIVE: The most challenging problem in diagnosing thyroid nodules is to distinguish benign disease from malignant disease.
  • Therefore, this study was designed to search for biological markers which can distinguish benign lesion from malignant lesion of thyroid.
  • METHODS: The expression of galectin-3 in 30 specimens of thyroid cancer, 10 specimens of thyroid adenoma, and 10 specimens of nodular thyroid goiter were detected by LSAB immunocytochemistry.
  • The results of routine pathologic examination of gland species were set as golden standard.
  • Galectin-3 was commonly expressed in well-differentiated thyroid carcinoma, but didn't express in thyroid adenoma and nodular thyroid goiter.
  • CONCLUSIONS: Galectin-3 is commonly expressed in thyroid malignant lesions, but not in benign lesions.
  • Immunocytochemistry assay can distinguish well-differentiated thyroid carcinoma from thyroid adnoma and nodular thyroid goiter.
  • [MeSH-major] Galectin 3 / metabolism. Thyroid Neoplasms / metabolism. Thyroid Nodule / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenoma / metabolism. Adenoma / pathology. Biopsy, Fine-Needle. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Gene Expression Regulation, Neoplastic. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Humans. Immunohistochemistry. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552965.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Galectin 3
  •  go-up   go-down






Advertisement